



CEU MATRIX

THE INSTITUTE FOR ADDICTION & CRIMINAL JUSTICE STUDIES

Presents

***TREATMENT FOR STIMULANT USE
DISORDERS (TIP 33) MODULE 1 (3
HOURS)***

Internet Based Coursework

3 hours of educational credit

Approved by such credentialing bodies as:

- *National Association of Alcoholism and Drug Abuse Counselors*
- *National Board of Certified Counselors*

(All approval bodies are listed at

<http://www.ceumatrix.com/accreditations.php>

Formerly CCJP.com

TREATMENT FOR STIMULANT USE DISORDERS (TIP 33) MODULE 1

Welcome to the growing family of coursework participants at CEU Matrix - The Institute for Addiction and Criminal Justice Studies.

This distance learning course package was developed for CEU Matrix John Tinsley, PhD. It is based on information found in SAMHSA Publication No. PEP21-02-01-004.

This package contains course materials, along with the post test and evaluation that are required to obtain the certificate of completion for the course. You may submit your answers online to receive the fastest response and access to your online certificate of completion. To take advantage of this option, simply access the Student Center at <http://www.ceumatrix.com/studentcenter>; login as a Returning Customer by entering your email address, password, and click on 'Take Exam'.

Copyright Notice

The documents and information on this Web site are copyrighted materials of CEU Matrix and its information providers. Reproduction or storage of materials retrieved from this service is subject to the U.S. Copyright Act of 1976, Title 17 U.S.C.

© Copyright 2025 CEUMatrix.

All rights reserved. Do not duplicate or redistribute in any form. Printed in the United States of America. No portion of this publication may be reproduced in any manner without the written permission of the publisher.

About the Instructor:

Dr. John H. Tinsley is a former assistant professor of Medical Physiology at the Texas A&M University System College of Medicine. He received his Ph.D. from Texas A&M University, College Station, Texas; M.S. from the University of North Carolina; and his B.S. from the University of Oklahoma.

He has been teaching, training, consulting and conducting research in the fields of Medical Physiology and Behavioral Biology for over twenty-nine years. Dr. Tinsley has authored over twenty-five professional and refereed articles, including invited reviews. He has been a member of the American Society for Physiology, and work done in 2001 led to an international award from The European Society on Microcirculation. Dr. Tinsley has received research funding from the Veteran's Administration, American Heart Association, and Scott and White Hospital. In addition, he has served on numerous review committees for national grant-funding agencies and scientific journals.

Using the Homepage for CEU Matrix - The Institute for Addiction and Criminal Justice Studies

The CEUMatrix – The Institute for Addiction and Criminal Justice Studies homepage (www.ceumatrix.com) contains many pieces of information and valuable links to a variety of programs, news and research findings, and information about credentialing – both local and national. We update our site on a regular basis to keep you apprised of any changes or developments in the field of addiction counseling and credentialing. Be sure to visit our site regularly, and we do recommend that you bookmark the site for fast and easy return.

TREATMENT FOR STIMULANT USE DISORDERS (TIP 33) MODULE 1

In Module 1 readers will learn about:

- Current rates of stimulant use disorders and overdose in the United States, including overdose involving the combination of stimulants with synthetic opioids (e.g., fentanyl) or semisynthetic opioids (e.g., heroin).
- Recent trends that are making stimulant use more lethal, such as the use of stimulants in combination with opioids or the increasing purity and decreasing price of cocaine and MA.
- The ongoing unmet treatment needs of people with stimulant use disorders, as well as the need for efforts to improve treatment retention.
- Rates of prescription stimulant misuse and how prescribers can help combat diversion.
- Legislation and regulations relevant to patients with stimulant use disorders and behavioral health and healthcare service providers who work with them.
- Neurological reinforcement systems (i.e., the reward system, the stress system) and other brain structures and mechanisms underlie the occurrence of stimulant use disorders and influence key aspects of stimulant use disorders, like craving and memory dysfunction.
- Brain imaging technology has played an important role in helping researchers and clinicians understand the ways in which short-and long-term stimulant use can affect the brain.
- Stimulants alter the dopamine system in ways that can affect substance use. For instance, increased feelings of pleasure and euphoria when using a stimulant can reinforce its use.
- Providers should be aware of the specific medical and psychological acute and chronic effects of each of the three main types of stimulants generally used by individuals with stimulant use disorders: cocaine, MA, and prescription stimulant medication, such as methylphenidate for ADHD.

Treatment for Stimulant Use Disorders

UPDATED 2021

TREATMENT IMPROVEMENT PROTOCOL

TIP 33

SAMHSA

Substance Abuse and Mental Health
Services Administration

Contents

Foreword	ix
Executive Summary	xi
Introduction	xi
Overall Key Messages	xii
Content Overview	xiii
TIP Development Participants	xvii
Consensus Panel	xvii
Field Reviewers	xviii
Resource Panel	xx
Editorial Advisory Board	xxi
Publication Information	xxiii
Chapter 1—Introduction	1
Purpose of the TIP	1
Organization of the TIP	2
Scope of the TIP	4
Current Stimulant Use in the United States	4
Importance of Science in Building Future Treatments	9
Summary	9
Chapter 2—How Stimulants Affect the Brain and Behavior	11
Substance Use Disorders	12
Neurobiology	14
The Reward System or Positive Reinforcement	14
The Stress System or Negative Reinforcement	15
Drug Craving and Memory	16
Role of Technologies	17
Stimulant Use and the Brain	19
Stimulants' Mechanisms of Action	19
General Effects of Stimulants	20
Effects of Route of Administration	22
Psychological and Neurocognitive Effects	22
Cocaine	22
Methamphetamine	25
Prescription Stimulant Medications	28
Assessment and Diagnosis	28
Summary	32



Chapter 3—Medical Aspects of Stimulant Use Disorders	33
Toxicity, Addiction, and Other Adverse Reactions	37
Intoxication	43
Clinical Manifestations and Medical Management	45
Identification and Management of Medical Complications	54
Identification and Management of Mental Complications	62
Co-Occurring Disorders and Conditions	67
Linking Treatment Programs and Medical Facilities	70
Summary	72
Chapter 4—Approaches to Treatment	73
How To Measure Effectiveness	74
Documented Psychosocial Treatment Approaches	76
Treatment Approaches With Supportive Research	83
Case Management and Coordinated Care	85
Other Interventions With Supportive Research	86
Other Models of Psychosocial Treatment	86
Clinical Issues To Consider	88
Summary	91
Chapter 5—Practical Application of Treatment Strategies	93
People With Stimulant Use Disorders Seeking Treatment	94
Treatment Needs of People With Cocaine Use Versus Methamphetamine Use Versus Prescription Stimulant Misuse	96
Maximizing Treatment Engagement	96
Assessment Procedures To Enhance Treatment Engagement	98
Staff Skills To Enhance Treatment Engagement	99
Treatment	100
Strategies for Engagement	100
Strategies for Treatment Initiation	105
Strategies for Stabilization	108
Strategies for Maintenance	113
Other Strategies Useful in Maintaining Abstinence	117
Next Steps	119
Summary	119
Chapter 6—Treatment Considerations for Special Populations	121
Racial/Ethnic Minority Populations	122
Women (Including Those Who Are Pregnant)	131
Men Who Have Sex With Men	135
Transgender and Gender Nonbinary Community	139
Adolescents	141
People Experiencing Homelessness/Unstable Housing	144

Rural Populations	145
People Involved in the Criminal Justice System	147
People Taking Medication for Opioid Use Disorder	149
People Who Inject Drugs	151
People Living With HIV/AIDS.	152
People With or At Risk for Hepatitis	155
Individuals With Co-Occurring Mental Disorders	157
Summary	163
Chapter 7—Resources	165
Resources for Counselors, Providers, and Programs	165
Publications.	168
Treatment Locators	174
Client and Family Resources.	175
Laws and Regulations.	177
Additional Resources	178
Bibliography	181

Exhibits

Exhibit 1.1. Key Terms	3
Exhibit 2.1. Brain Structures Involved in the Reward System	13
Exhibit 2.2. Normal Dopamine Transmission	16
Exhibit 2.3. Continuum of Psychostimulant Activation	21
Exhibit 2.4. Acute Effects of Cocaine on Dopamine Transmission	23
Exhibit 2.5. Acute Effects of Methamphetamine on Dopamine Transmission	25
Exhibit 2.6. Key Terms	26
Exhibit 3.1. Key Terms	34
Exhibit 3.2. Effects of Route of Use for Cocaine, Methamphetamine, and Prescription Stimulants	38
Exhibit 3.3. Differences Between Cocaine, Methamphetamine, and Prescription Stimulants	39
Exhibit 3.4. Common Signs and Symptoms of Acute Stimulant Intoxication	42
Exhibit 3.5. Common Signs and Symptoms of Stimulant Withdrawal/ Abstinence Syndrome	48
Exhibit 3.6. Common Symptoms of Chronic Stimulant Use or Prescription Stimulant Misuse	52
Exhibit 3.7. Distinctive Indicators of Chronic Use of Cocaine and Methamphetamine, and Chronic Misuse of Prescription Stimulants	52
Exhibit 3.8. AGRO+ Method for Deescalation With Aggressive Patients	65
Exhibit 4.1. Stimulant Use: Managing Common Clinical Issues	89
Exhibit 5.1. Key Terms	104
Exhibit 6.1. Key Terms	139
Exhibit 6.2. Estimated Per-Act Probability of Acquiring HIV From an Infected Source by Exposure Act*	153
Exhibit 6.3. Hepatitis Risk and Prevention for People Who Use Stimulants	156

Foreword

The Substance Abuse and Mental Health Services Administration (SAMHSA) is the U.S. Department of Health and Human Services agency that leads public health efforts to reduce the impact of substance abuse and mental illness on America's communities. An important component of SAMHSA's work is focused on dissemination of evidence-based practices and providing training and technical assistance to healthcare practitioners on implementation of these best practices.

The Treatment Improvement Protocol (TIP) series contributes to SAMHSA's mission by providing science-based, best-practice guidance to the behavioral health field. TIPs reflect careful consideration of all relevant clinical and health services research, demonstrated experience, and implementation requirements. Select nonfederal clinical researchers, service providers, program administrators, and patient advocates comprising each TIP's consensus panel discuss these factors, offering input on the TIP's specific topics in their areas of expertise to reach consensus on best practices. Field reviewers then assess draft content and the TIP is finalized.

The talent, dedication, and hard work that TIP panelists and reviewers bring to this highly participatory process have helped bridge the gap between the promise of research and the needs of practicing clinicians and administrators to serve, in the most scientifically sound and effective ways, people in need of care and treatment of mental and substance use disorders.

My sincere thanks to all who have contributed their time and expertise to the development of this TIP. It is my hope that clinicians will find it useful and informative to their work.

Miriam E. Delphin-Rittmon, Ph.D.

Assistant Secretary for Mental Health and Substance Use
U.S. Department of Health and Human Services
Substance Abuse and Mental Health Services Administration

Executive Summary

Introduction

Since the 1980s, stimulant use has wreaked havoc on individuals and communities across the United States and has prompted strong responses from federal, state, and local governments and organizations. For example, the relatively minor problems caused by cocaine use in the 1960s and 1970s have grown to become major medical and law enforcement issues.

Similarly, the increasing use of methamphetamine (MA) has led policymakers, public officials, and service providers to increase efforts to fight its spread. For example, concerns that MA use would become epidemic led to passage of the Combat Methamphetamine Epidemic Act of 2005 and the incorporation of MA-specific provisions in the Comprehensive Addiction and Recovery Act of 2016. Misuse of prescription stimulants such as methylphenidate has also become a growing concern.

The explosive growth of stimulant use has also triggered a flurry of research. The results are tremendous advances in understanding stimulant use disorders, the basic functioning of the brain, and substance use disorders (SUDs) in general. Yet reports that describe the fundamentals of stimulant use disorder treatment and the success of various treatment interventions are still needed.

This Treatment Improvement Protocol (TIP) reviews what is currently known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and MA and the misuse of prescribed stimulants (such as those for the treatment of attention deficit hyperactivity disorder [ADHD]).


The scientifically based information in this TIP is presented in a manner that makes it accessible and relevant to behavioral health service clinicians and other frontline SUD treatment providers, including healthcare service providers (e.g., in primary care settings, in emergency departments). The TIP offers recommendations on treatment approaches, strategies for planning and initiating treatment, recommendations on how to maximize treatment engagement and retention, and strategies for initiating and maintaining abstinence. Also included are recommendations for the medical management of people who use stimulants and recommendations regarding special populations and settings.

The Substance Abuse and Mental Health Services Administration (SAMHSA) first published this TIP in 1999. SAMHSA implemented a full-scale review and revision of the original TIP. Content now addresses:

- Recent research on stimulant use disorders.
- The increasing number of overdose deaths in the United States attributable to cocaine and MA (especially when combined with other substances, like synthetic and semisynthetic opioids).
- The rise in the use and misuse of prescription stimulants (leading to increased risk and incidence of diversion).

This TIP revision:

- Uses terminology that is person centered and aligned with language in the latest edition of the *Diagnostic and Statistical Manual of Mental Disorders*.
- Incorporates findings from research published since 2010 (and where possible, since 2016).
- Includes key messages at the beginning of every chapter to guide readers in understanding from the outset the core content they are about to read.
- Updates statistics and related information about stimulant use, treatment, overdose, and legislation in the United States.



- Provides a more focused discussion of the neurobiology of stimulant use disorders than the original TIP's broad primer on the topic.
- Reflects updated empirical evidence that supports using contingency management (CM), cognitive-behavioral therapy (CBT), community reinforcement, and motivational interviewing (MI) to treat stimulant use disorders—as well as recent evidence for other nonpharmacologic treatments with some support (like exercise and mindfulness techniques).
- Includes no discussion of pharmacotherapy options, given that all prescribing for stimulant use disorders is done off label (that is, no Food and Drug Administration [FDA]-approved medication for any stimulant use disorder currently exists).
- Expands the discussion of special populations with unique treatment needs to cover racial/ethnic minorities, women (including those who are pregnant), men who have sex with men (MSM), transgender and gender nonbinary community members, adolescents, people experiencing homelessness/unstable housing, rural populations, people involved with the criminal justice system, people taking opioid use disorder medication, people who inject drugs, people with or at risk for HIV/AIDS, people with or at risk for hepatitis, and individuals with co-occurring mental disorders.

The purpose of this TIP is to advance the understanding of treating the SUDs associated with the use of cocaine and MA and the misuse of prescription stimulants. This TIP is organized to guide behavioral health service providers, healthcare service providers, and other addiction and allied professionals sequentially through the primary components of proper identification and management of stimulant use disorders. The TIP is divided into seven chapters so that readers can easily find the material they need most. Below is a summary of the TIP's main points and brief summaries of the first six chapters. (The seventh chapter is a listing of resources.)

Overall Key Messages

Stimulant use disorders are a growing problem in the United States, with more than 5 million people age 12 and older reporting past-year cocaine use, nearly 2 million reporting MA use, and almost 5 million reporting prescription stimulant misuse in 2019. Stimulant-related overdose fatalities are also on the rise, with the incidence of stimulant-related deaths more than tripling between 2010 and 2017.

Stimulant use disorders have a powerful neurobiological basis that includes changes in brain chemistry and functioning that in turn help drive stimulant use behaviors. But stimulant use disorders also have a social and environmental component that clinicians need to consider in trying to understand patients' stimulant use behaviors, difficulties in achieving and maintaining abstinence, and potential unwillingness to engage in formal SUD treatment.

Healthcare providers need to understand the medical complications of stimulant use, their clinical signs and symptoms, and appropriate management approaches. Behavioral health service providers should learn to recognize the medical complications of stimulant use so they can make quick and successful referrals to medical treatment as needed.

Ample research supports the use of CM as the primary psychosocial treatment for stimulant use disorders. The lack of FDA-approved pharmacotherapies for stimulant use disorders makes it vital for clinicians to learn about and offer psychosocial interventions (e.g., CM, CBT) and other nonpharmacologic services that have empirical support (e.g., mindfulness practices, family/couples counseling, the Matrix model of treatment).

Clinicians should consider a variety of factors in assessing why people with stimulant use disorders have sought treatment and what their individual treatment needs are. Clinicians can make treatment engagement—as well as treatment completion—more likely by maximizing access; addressing treatment ambivalence; training staff on how to provide respectful, patient-centered services; developing a well-thought-out treatment plan; and using techniques that help patients initiate and maintain abstinence.

Certain populations may be at an increased risk for stimulant use or, once they start using stimulants, may be at higher risk for negative outcomes (like contracting HIV). **Such populations—including women, people living in rural areas, people of diverse racial/ethnic backgrounds, MSM, and people experiencing homelessness/housing instability—may benefit from targeted treatment engagement techniques, interventions, and monitoring approaches that are tailored to their unique needs and challenges.**

Content Overview

This TIP is divided into seven chapters designed to thoroughly cover all relevant aspects of stimulant use disorders.

Chapter 1: Introduction

This chapter provides a broad introduction to stimulant use disorders and trends in stimulant use in the United States. The chapter also describes the goals and scope of the TIP as well as its intended audiences.

In Chapter 1, readers will learn about:

- Current rates of stimulant use disorders and overdose in the United States, including overdose involving the combination of stimulants with synthetic opioids (e.g., fentanyl) or semisynthetic opioids (e.g., heroin).
- Recent trends that are making stimulant use more lethal, such as the use of stimulants in combination with opioids or the increasing purity and decreasing price of cocaine and MA.
- The ongoing unmet treatment needs of people with stimulant use disorders, as well as the need for efforts to improve treatment retention.
- Rates of prescription stimulant misuse and how prescribers can help combat diversion.
- Legislation and regulations relevant to patients with stimulant use disorders and behavioral health and healthcare service providers who work with them.

Chapter 2: How Stimulants Affect the Brain and Behavior

This chapter reviews the ways in which brain structures, functions, and neurochemistry are altered in the presence of stimulants. The chapter also looks at the role of these alterations in the development and persistence of a stimulant use disorder.

In Chapter 2, readers will learn that:


- Neurological reinforcement systems (i.e., the reward system, the stress system) and other brain structures and mechanisms underlie the occurrence of stimulant use disorders and influence key aspects of stimulant use disorders, like craving and memory dysfunction.
- Brain imaging technology has played an important role in helping researchers and clinicians understand the ways in which short- and long-term stimulant use can affect the brain.
- Stimulants alter the dopamine system in ways that can affect substance use. For instance, increased feelings of pleasure and euphoria when using a stimulant can reinforce its use.
- Providers should be aware of the specific medical and psychological acute and chronic effects of each of the three main types of stimulants generally used by individuals with stimulant use disorders: cocaine, MA, and prescription stimulant medication, such as methylphenidate for ADHD.

Chapter 3: Medical Aspects of Stimulant Use Disorders

This chapter describes medical and psychological signs, symptoms, and complications associated with stimulant use and stimulant use disorders and how to best manage common complications.

In Chapter 3, readers will learn that:

- The signs, symptoms, and harmful effects of stimulant use will vary depending on route of administration, dose, drug purity, level of intoxication, experience of withdrawal, chronicity, use history, and more.



- Medical complications of stimulant use can be serious and in some cases life threatening; these complications include cardiovascular disease, respiratory effects, cerebrovascular dysfunction, muscular and renal toxicity, gastrointestinal complaints, infections (including HIV), and hepatitis.
- Psychological complications include psychosis, aggression, and violence.
- People with stimulant use disorders often grapple with co-occurring disorders and conditions that can complicate diagnosis, treatment, and recovery. These disorders and conditions are secondary substance use (especially co-occurring opioid use), specific mental disorders (e.g., depression, anxiety, ADHD), medical conditions (e.g., dental problems, vein and nerve damage in the arm, cardiovascular disorders), and traumatic injury (e.g., due to violence/physical altercations).
- Patients' psychological reactions to stimulant use, like psychosis and violent behaviors, can also result in self-harm or harm to others if not managed properly.
- Coordinated care between medical and SUD treatment programs is a major aspect of properly identifying and treating co-occurring disorders and conditions of people with stimulant use disorders. Many patients will first appear for treatment or services in non-SUD settings—mainly primary care clinics and emergency departments.
- CM is by far the psychosocial treatment with the greatest scientific support. In some studies, CM is even more effective when used in combination with other psychosocial treatments, like community reinforcement.
- After CM, the three other psychosocial interventions with the most support are CBT, community reinforcement, and MI.
- Other forms of psychosocial treatment with less but still some support are the Matrix model, behavioral family or couples therapy, and case management/coordinated care.
- There is growing evidence that physical exercise, mindfulness, and transcranial magnetic stimulation also may help people with stimulant use disorders reduce their stimulant use or otherwise improve their health and well-being.
- Not all people with stimulant use disorders will be interested in formal SUD treatment. Offering harm reduction tools and strategies is critical because they can help people who continue to use stimulants stay alive. Harm reduction involves providing access to or information about:
 - Needle/syringe exchanges.
 - Fentanyl test strips (to determine whether drugs have been laced with fentanyl).
 - The opioid overdose reversal agent naloxone.
 - HIV prevention education.
- Rather than using a cookie-cutter approach to treatment selection (e.g., sending all patients to 60-day residential treatment), clinicians should consider each individual's unique SUD history and treatment needs and preferences. The American Society of Addiction Medicine's patient placement criteria can help guide the treatment selection process.

Chapter 4: Approaches to Treatment

This chapter describes the best supported nonpharmacologic approaches to helping patients begin and sustain recovery from stimulant use disorders.

In Chapter 4, readers will learn that:

- There are no FDA-approved medications for managing stimulant use disorders. This makes understanding available nonpharmacologic treatment options imperative.

Chapter 5: Practical Application of Treatment Strategies

This chapter briefly summarizes techniques clinicians can use to help engage patients in SUD treatment and maximize their chances of sustaining long-term recovery.

In Chapter 5, readers will learn that:

- People seek treatment for any number of reasons, and clinicians will better understand how to help their patients engage and stay in treatment if they know why their patients are entering treatment.
- Factors that can make treatment engagement more likely include:
 - Identifying barriers to treatment engagement.
 - Making treatment highly accessible.
 - Providing support for treatment participation.
 - Offering multiple treatment options.
 - Discussing with patients their expectations for treatment and any ambivalence they may have about treatment.
 - Working collaboratively with patients to develop a clear, flexible treatment framework.
- Staff should be educated about how to provide person-centered, respectful, empathic services, which can help encourage patients to stay engaged in treatment.
- To start treatment off “on the right foot,” clinicians should work with patients to set their treatment goals, fully assess their clinical needs, discuss reducing or discontinuing all substance use, and help them manage stimulant withdrawal symptoms.
- Treatment retention is critical. Simply put, people are less likely to die when in treatment than when not in treatment. Any amount of time people with stimulant use disorders remain in treatment is an opportunity for them to stay alive and improve their health.
- Many strategies can help patients maintain progress in recovery, such as teaching functional analysis of stimulant use; reinforcing positive behaviors with incentives; teaching strategies to avoid high-risk situations; offering relapse prevention techniques; and promoting connections to family, friends, and the community.
- Other services that can help patients maintain recovery are vocational counseling, social skills training, relationship counseling, mutual-help support programs, and wellness counseling. Clinicians should offer referrals for these services as needed.

Chapter 6: Treatment Considerations for Special Populations

This chapter discusses numerous populations that may be at increased risk for developing a stimulant use disorder or for experiencing negative outcomes associated with stimulant use (e.g., contracting HIV or hepatitis) and prescription stimulant misuse. These populations may require tailored assessment, treatments, or education to meet their unique needs and circumstances.

In Chapter 6, readers will learn that:

- Vulnerable populations are people of diverse racial/ethnic backgrounds, women (including those who are pregnant), MSM, transgender and gender nonbinary communities, adolescents, people experiencing homelessness/unstable housing, rural populations, people involved in the criminal justice system, people taking medication for opioid use disorder, people who inject drugs, people with or at risk for HIV/AIDS and hepatitis, and individuals with co-occurring mental disorders.
- Populations that experience health disparities related to systems of care and engagement in care may have higher rates of stimulant use disorder and increased issues accessing care for stimulant use disorders. They may also be more likely to experience secondary negative consequences related to these vulnerabilities (e.g., trauma or communicable diseases).
- By understanding the needs, SUD care access issues, and treatment considerations of these populations, clinicians will be more likely to provide patient-centered, effective care that maximizes rapport and treatment engagement.
- Services can be tailored to each of these populations to account for their unique risk factors, patterns of use, and health considerations. Clinicians may need to seek guidance from experts in these populations when tailoring treatment.

TIP Development Participants

Note: The information given for participants in the TIP's development indicates their affiliations at the time of their participation and may not reflect their current affiliations.

Consensus Panel

Each Treatment Improvement Protocol's (TIP) consensus panel is a group of primarily nonfederal addiction-focused clinical, research, administrative, and recovery support experts with deep knowledge of the TIP's topic. With the Substance Abuse and Mental Health Services Administration's Knowledge Application Program team, members of the consensus panel develop each TIP via a consensus-driven, collaborative process that blends evidence-based, best, and promising practices with the panel members' expertise and combined wealth of experience.

Chair

Richard A. Rawson, Ph.D.
Executive Director
Matrix Center and Matrix Institute on Addiction
Deputy Director
UCLA Addiction Medicine Services
Los Angeles, CA

Workgroup Leaders

Felipe G. Castro, Ph.D., M.S.W.
Professor
Hispanic Research Center
Department of Psychology
Arizona State University
Tempe, AZ

James W. Cornish, M.D.
Assistant Professor of Psychiatry
Director
Division of Pharmacotherapy
Treatment Research Center
University of Pennsylvania
Department of Veterans Affairs Medical Center
Philadelphia, PA

Frances R. Levin, M.D.
Assistant Professor
Clinical and Educational Activities
Division on Substance Abuse
Columbia University
New York, NY

Michael J. McCann, M.A.
Research Coordinator
Matrix Center
Los Angeles, CA

Panelists


Arlene Hall, RN, M.S., CD
Director of Nursing
Hope House
Crownsville, MD

Stephen Higgins, Ph.D.
Professor
Departments of Psychiatry and Psychology
Ira Allen School
University of Vermont
Burlington, VT

Kyle M. Kampman, M.D.
Assistant Professor of Psychiatry
Treatment Research Center
University of Pennsylvania
Philadelphia, PA

Quintin Kingfisher
Medical Resources
Tribal Health
Lame Deer, MT

Judy Knobbe, M.S.W., LISW, CADC
Director
Heart of Iowa
Area Substance Abuse Council
Cedar Rapids, IA

**Wendy Lay**

Program Specialist
Bureau of Alcohol and Drug Abuse
State of Nevada
Carson City, NV

Scott M. Reiner, M.S., CAC, CCS

Substance Abuse Program Supervisor
Substance Abuse Services Unit
Virginia Department of Juvenile Justice
Richmond, VA

Ewa Szumotalska Stamper, Ph.D.

Police Psychologist
Honolulu Police Department
Private Practice, Clinical and Addictions Psychology
Honolulu, HI

Arnold M. Washton, Ph.D.

Private Practice of Addiction Psychology
Parkland, FL

Dennis A. Weis, M.D.

Medical Director
Powell Center for Disease Control
Iowa Lutheran Hospital
President, Iowa Chapter
American Society of Addiction Medicine
Des Moines, IA

Field Reviewers

Field reviewers represent each TIP's intended target audiences. They work in addiction, mental health, primary care, and adjacent fields. Their direct frontline experience related to the TIP's topic allows them to provide valuable input on a TIP's relevance, utility, accuracy, and accessibility. Additional advisors to this TIP include members of a resource panel and an editorial advisory board.

Original Field Reviewers

Patricia Bradford, LISW, LMFT, CTS

P.A. Bradford and Associates
Columbia, SC

Peter J. Cohen, M.D., J.D.

Special Expert
Medications Development Division
National Institute on Drug Abuse
National Institutes of Health
Bethesda, MD

Carol L. DeRosa, RN

Registered Nurse Consultant
Child Advocacy Unit
Anne Arundel County Department of Social Services
Severna Park, MD

Karen Kelly-Woodall, M.S., MAC, NCAC II

Criminal Justice Coordinator
Cork Institute
Georgia Addiction Technology Transfer Center
Morehouse School of Medicine
Atlanta, GA

Mitchell Markinem, M.A., NCAC II

Drug Court Program Coordinator
Fifth Circuit Solicitor's Office
Columbia, SC

Bonnie I. Pipe, B.S., CCDC

Clinical Director
Northern Cheyenne Recovery Center
Northern Cheyenne Board of Health
Lame Deer, MT

Lynda A. Price, Ph.D., ICADC

Treatment Coordinator
Global House
National Drug Commission
Hamilton, BD

Margaret M. Salinger, M.S.N., RN, CARN

National Nurses Society on Addiction
Department of Veterans Affairs Medical Center
Coatesville, PA

Richard E. Steinberg, M.S.

President
WestCare
Las Vegas, NV

Christopher J. Stock, Pharm.D.

Clinical Pharmacist
Substance Abuse Program
Veterans Medical Center
Salt Lake City, UT

Richard T. Suchinsky, M.D.

Associate Director for Addictive Disorders and
Psychiatric Rehabilitation
Department of Veterans Affairs
Mental Health and Behavioral Sciences Services
Washington, DC

Sushma Taylor, Ph.D.

Executive Director
Administrative Office
Center Point, Inc.
San Rafael, CA

Elizabeth Wells, Ph.D.

Research Associate Professor
Department of Psychiatry and Behavioral Sciences
University of Washington
Seattle, WA

2021 Update Field Reviewers**Justin Alves, RN, MSN, ACRN, CARN, CNE**

Addiction Nurse Educator
Office-Based Addiction Treatment Training and
Technical Assistance
Boston Medical Center
Clinical Instructor, Public Health
Northeastern University
Boston, MA

Amelia M. Arria, Ph.D.

Professor
Department of Behavioral and Community Health
Director
Center on Young Adult Health and Development
University of Maryland School of Public Health
College Park, MD

Wanda Barnett, M.S.

Primary Therapist – Addiction/Co-Occurring
Disorders
Retreat at Lancaster County
Retreat Behavioral Health
Ephrata, PA

Adam D. Bloom, M.S., LCPC, LPC, NCC, MAC

Clinical Director
Kolmac Outpatient Recovery Centers
Burtonsville, MD

Lucy R. Cannon, Ed.D., M.S.W., LCSW, LICSW, CCDP-D, MATS

Owner/Chief Executive Officer
LEJ Behavioral Health Services, LLC
Redan, GA
Adjunct Professor
Clark Atlanta University
Atlanta, GA

Mark Depman, M.D.

Attending Physician
Department of Emergency Medicine
Central Vermont Medical Center – University of
Vermont Health Network
Berlin, VT

Thomas E. Freese, Ph.D.

Co-Director
UCLA Integrated Substance Abuse Programs
Adjunct Professor
UCLA David Geffen School of Medicine
Los Angeles, CA

Peggy J. Gemperline, RN, B.S.N., M.B.A.


Vice President of Residential and Ambulatory
Services
Pinnacle Treatment Centers
Mt. Laurel, NJ

Amy Jeppesen, M.S.W., LCSW, ACADC

Behavioral Health Director Idaho/Iowa
Trivium Life Services
Adjunct Faculty
Boise State University
Boise, ID

Philip T. McCabe, CSW, CAS, CDVC, DRCC

President, NALGAP
The Association of Lesbian, Gay, Bisexual,
Transgender Addiction Professionals and their
Allies
Health Educator
Center for Public Health Workforce Development
Rutgers School of Public Health
Piscataway, NJ

**Mary McCarty-Arias, M.A.**

Rehabilitation Counselor and Trainer
Northeast Caribbean Addiction Treatment and Transfer Center
New York State Psychiatric Institute
Department of Psychiatry
Columbia University Medical Center
New York, NY

Larissa Mooney, M.D.

Director
University of California, Los Angeles
Addiction Psychiatry Division
Associate Professor of Psychiatry
University of California Los Angeles
Los Angeles, CA

Diana Padilla, RCR, CASAC-T

Research Project Manager
Northeast Caribbean Addiction Treatment and Transfer Center
Division on Substance Use Disorders, New York State Psychiatric Institute
Department of Psychiatry
Columbia University Medical Center
New York, NY

Jacynth (Jass) Pelland, M.S.W., LCSW, ACSW, LCADC, CJC

Program Coordinator
Intensive Recovery Treatment Support (IRTS)
Rutgers University Behavioral Health Center—Community Based Services
Rutgers School of Public Health
Piscataway, NJ

Saverio (Sam) Pirozzi, Ed.D., Ed.S., LMFT, LCADC, LPC

Private Practitioner & Consultant/Trainer
Stanhope, NJ, and Myrtle Beach, SC

John M. Roll, Ph.D.

Professor and Vice Dean of Research
Elson S. Floyd College of Medicine and College of Nursing
Washington State University
Spokane, WA

Kenneth Andrew Saffier, M.D.

President
Medical Education & Research Foundation for the Treatment of Addiction
Medical Director
National Coalition Against Prescription Drug Abuse
Medical Director
Bi-Bett, Inc.
Independent contractor/consultant
UCLA Integrated Substance Abuse Programs
University of California Los Angeles
Los Angeles, CA

Lisa L. Weyandt, Ph.D.

Licensed Psychologist
Director, Interdisciplinary Neuroscience Program
Professor, Department of Psychology
University of Rhode Island
Kingston, RI

Resource Panel

Patrick Carpenter

Policy Analyst
Executive Office of the President
Office of National Drug Control Policy
Washington, DC

Johanna Clevenger, M.D.

Chief
Alcoholism and Substance Abuse Program Branch
Indian Health Service
Rockville, MD

Peter J. Cohen, M.D., J.D.

Special Expert
Medications Development Division
National Institute on Drug Abuse
National Institutes of Health
Bethesda, MD

Jerome Jaffe, M.D.

Director
Office of Evaluation, Scientific Analysis and Synthesis
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services Administration
Rockville, MD

George Kanuck

Office of Policy Coordination and Planning
Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services
Administration
Rockville, MD

Kate Malliarakis, CNP, M.S.M., NCADC II

Executive Office of the President
Office for Demand Reduction
Office of National Drug Control Policy
Washington, DC

Eleanor Sargent, CAC, NCAC, M.A.

Director
Clinical Issues
NAADAC, The Association for Addiction
Professionals
Arlington, VA

Editorial Advisory Board**Karen Allen, Ph.D., RN, CARN**

Professor and Chair
Department of Nursing
Andrews University
Berrien Springs, MI

Richard L. Brown, M.D., M.P.H.

Associate Professor
Department of Family Medicine
University of Wisconsin School of Medicine
Madison, WI

Dorynne Czechowicz, M.D.

Associate Director
Medical/Professional Affairs
Treatment Research Branch
Division of Clinical and Services Research
National Institute on Drug Abuse
National Institutes of Health
Rockville, MD

Linda S. Foley, M.A.

Former Director
Project for Addiction Counselor Training
National Association of State Alcohol and Drug
Abuse Directors
Washington, DC

Wayde A. Glover, M.I.S., NCAC II

Director
Commonwealth Addictions Consultants and
Trainers
Richmond, VA

Pedro J. Greer, M.D.

Assistant Dean for Homeless Education
University of Miami School of Medicine
Miami, FL

Thomas W. Hester, M.D.

Former State Director
Substance Abuse Services
Division of Mental Health, Mental Retardation and
Substance Abuse
Georgia Department of Human Resources
Atlanta, GA

James G. (Gil) Hill, Ph.D.

Director
Office of Substance Abuse
American Psychological Association
Washington, DC

Douglas B. Kamerow, M.D., M.P.H.


Director
Office of the Forum for Quality and Effectiveness in
Health Care
Agency for Healthcare Research and Quality
Rockville, MD

Stephen W. Long

Director
Office of Policy Analysis
National Institute on Alcohol Abuse and Alcoholism
National Institutes of Health
Rockville, MD

Richard A. Rawson, Ph.D.

Executive Director
Matrix Center and Matrix Institute on Addiction
Deputy Director
UCLA Addiction Medicine Services
Los Angeles, CA

**Ellen A. Renz, Ph.D.**

Former Vice President of Clinical Systems
MEDCO Behavioral Care Corporation
Kamuela, HI

Richard K. Ries, M.D.

Director and Associate Professor
Outpatient Mental Health Services and Dual
Disorder Programs
Harborview Medical Center
Seattle, WA

Sidney H. Schnoll, M.D., Ph.D.

Chairman
Division of Substance Abuse Medicine
Medical College of Virginia
Richmond, VA

Publication Information

Acknowledgments

This publication was prepared under contract numbers 270-95-0013 and 283-17-4901 by the Knowledge Application Program (KAP) for the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS). Sandra Clunies, M.S., ICADC, served as the Contracting Officer's Representative (COR) for initial TIP development. Suzanne Wise served as the COR, and Robert Baillieu, M.D., M.P.H., as the Project Champion, for the TIP update.

Disclaimer

The views, opinions, and content expressed herein are the views of the consensus panel members and do not necessarily reflect the official position of SAMHSA or HHS. No official support of or endorsement by SAMHSA or HHS for these opinions or for the instruments or resources described is intended or should be inferred. The guidelines presented should not be considered substitutes for individualized client care and treatment decisions.

Public Domain Notice

All materials appearing in this volume except those taken directly from copyrighted sources are in the public domain and may be reproduced or copied without permission from SAMHSA or the authors. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, HHS.

Electronic Access and Copies of Publication

This publication may be ordered or downloaded from SAMHSA's Publications and Digital Products webpage at store.samhsa.gov. Or, please call SAMHSA at 1-877-SAMHSA-7 (1-877-726-4727) (English and Español).

Recommended Citation

Substance Abuse and Mental Health Services Administration. *Treatment for Stimulant Use Disorders*. Treatment Improvement Protocol (TIP) Series 33. SAMHSA Publication No. PEP21-02-01-004. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2021.


Originating Office

Office of Program Analysis and Coordination, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857.

Nondiscrimination Notice

SAMHSA complies with applicable federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. SAMHSA cumple con las leyes federales de derechos civiles aplicables y no discrimina por motivos de raza, color, nacionalidad, edad, discapacidad, o sexo.

SAMHSA Publication No. PEP21-02-01-004
First printed 1999
Updated 2021



Chapter 1—Introduction


KEY MESSAGES

- Stimulant use disorders are a major public health concern in the United States, with more than 5 million people age 12 and older reporting past-year cocaine use, nearly 2 million reporting methamphetamine use, and almost 5 million reporting prescription stimulant misuse in 2019.
- Overdose deaths from stimulants have been increasing over the past 20 years, especially deaths attributable to stimulants taken with either synthetic opioids (e.g., fentanyl) or semisynthetic opioids (e.g., heroin). This underscores the importance of (1) having behavioral health and healthcare service providers understand and educate patients about the dangers of stimulant use disorders and (2) creating easy access to screening and treatment.
- Effective treatments for stimulant use disorders are available, but more behavioral health and healthcare service providers need to learn about these treatments and understand how and why to offer them to patients.

Chapter 1 of this Treatment Improvement Protocol (TIP) lays the groundwork for understanding the scope and effects of stimulant use disorders in the United States. The TIP generally uses the plural term “stimulant use disorders”—rather than the singular term “stimulant use disorder” found in the fifth edition of the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-5; American Psychiatric Association [APA], 2013)—to reflect that patients may well misuse multiple substances classified as stimulants, including nonprescription stimulants. The plural term also conveys the purpose of this TIP—helping clinicians combat stimulant use and stimulant-related problems. This chapter will benefit all behavioral health and healthcare service providers who encounter patients with stimulant use disorders by giving a broad overview of why stimulant use disorders are so harmful and how information in this TIP can be leveraged to bring about more timely and effective management of these disorders.

Purpose of the TIP

Major U.S. institutions responded slowly to the dangers of stimulants throughout the 1970s and 1980s, partly because researchers and clinicians had only a partial picture of the basic biologic and psychological effects of these powerful psychostimulants. Knowledge gained over the past four decades about the properties of these substances can help clinicians understand, prevent, and treat the problems created by the use of cocaine and methamphetamine (MA) and the misuse of prescription stimulant medications (e.g., methylphenidate). This TIP summarizes the latest research as well as firsthand clinical experience of substance use disorder (SUD) treatment professionals.



Since the mid-1980s, there has been an explosion of knowledge about the effects of stimulants. Because these psychostimulants alter the functioning of the body and the brain, physicians and physician assistants, nurses and nurse practitioners, psychologists, social workers, licensed professional counselors, marriage and family counselors, SUD counselors, other behavioral health service providers, and peer recovery support specialists must understand the biologic aspects of stimulant use disorders. New areas of expertise include pharmacology, genomics, neurobiology, psychiatric and psychological manifestations, and treatment approaches for stimulant use disorders.

Stimulant use disorders do more than harm the people who have them. They can also negatively affect the lives of these individuals' family members, friends, neighbors, and coworkers. This wider effect makes it all the more important to help individuals with stimulant use disorders engage in SUD treatments and services.

This TIP presents current knowledge about the nature and treatment of stimulant use disorders. Because the Food and Drug Administration (FDA) has to date not approved any medications for stimulant use disorders, this TIP does not discuss pharmacology as a treatment strategy. The TIP is designed to provide scientifically established information about the effects of stimulants in a manner that makes it available and relevant for frontline treatment providers. In addition, the document reviews what is known about treating the medical, psychiatric, and SUD problems associated with the use of cocaine and MA and misuse of prescription stimulants. The treatment section emphasizes those approaches that have empirical support.

Organization of the TIP

This TIP opens with a broad overview of the current state of stimulant use disorders in the United States (Chapter 1) and then moves into the neurobiologic aspects (Chapter 2), assessment and diagnosis (Chapter 2), and medical management (Chapter 3) of stimulant use disorders. Chapter 4 introduces readers to empirically supported nonpharmacologic treatments for stimulant use disorders, and Chapter 5 takes an in-depth look at important clinical factors affecting the full continuum of care, including treatment initiation and abstinence maintenance. Chapter 6 discusses stimulant use among a range of special populations and specific considerations to improve engagement and treatment for the described populations. Finally, Chapter 7 provides a compendium of resources, including links to online information and tools.

Exhibit 1.1 defines important terms used in this publication. Also, note that the term “clinician” covers all healthcare providers and behavioral health service providers who work with people with stimulant use disorders and other SUDs. This could include psychologists, psychiatrists, national certified addiction counselors, licensed alcohol and drug counselors, marriage and family therapists, social workers, licensed professional counselors, physicians, nurses, and advanced practice healthcare providers (e.g., nurse practitioners, physician assistants). However, this term does not refer to peer recovery support specialists. Also, the TIP uses the term “patients” rather than “clients” or “consumers” to refer to people who are receiving any preventive services or care for stimulant use disorders or related conditions.





EXHIBIT 1.1. Key Terms

- **Craving:** A powerful desire for drugs.
- **Designer drug:** A synthetic analog of a restricted drug; has psychoactive properties.
- **Drug diversion:** The illegal distribution or use of prescription drugs or their use for purposes not intended by the prescriber (Centers for Medicare & Medicaid Services, 2016).
- **Physical dependence:** An adaptive physiological state that occurs with regular drug use and results in a withdrawal syndrome when drug use stops.
- **Stimulant use disorder:** According to DSM-5 (APA, 2013), a diagnosis based on the occurrence of at least two of the following criteria within a 12-month period (or 12 months before incarceration): (1) taking more of the stimulant than intended; (2) failing to reduce or control stimulant use, despite a wish or efforts to do so; (3) devoting excessive amounts of time to activities related to stimulant use; (4) having cravings or urges for the stimulant; (5) not meeting obligations at home, school, or work; (6) continuing to take stimulants, even if this use has led to or increased relationship or social difficulties; (7) forgoing or limiting important recreational, social, or job-related activities because of stimulant use; (8) taking stimulants in situations where doing so is physically hazardous; (9) continuing to take stimulants despite the realization that doing so has probably caused or aggravated a physical or psychological problem; (10) developing tolerance to the stimulants; and (11) experiencing withdrawal symptoms when stimulants are not taken or taking stimulants to ease or prevent withdrawal symptoms (Substance Abuse and Mental Health Services Administration, 2020m).
- This TIP uses the terms **amphetamine use disorder**, **cocaine use disorder**, and **methamphetamine use disorder** (or **MA use disorder**). Although these terms do not appear in DSM-5, they are used in research and survey literature. (Amphetamine use disorder and cocaine use disorder were classified as separate disorders in the previous edition of DSM.)
- **Substance misuse*:** The use of any substance in a manner, situation, amount, or frequency that can cause harm to users or to those around them. In the case of prescription medications, misuse is any use other than as prescribed or directed by a healthcare professional. For some substances or individuals, any use would constitute misuse (e.g., injection drug use).
- **Substance use disorder (SUD)*:** A medical illness caused by repeated misuse of a substance or substances. According to DSM-5 (APA, 2013), SUDs are characterized by clinically significant impairments in health and social function and by impaired control over substance use. They are diagnosed through assessing cognitive, behavioral, and psychological symptoms. SUDs range from mild to severe and from temporary to chronic. They typically develop gradually over time with repeated misuse, leading to changes in brain circuits governing incentive salience (the ability of substance-associated cues to trigger substance seeking), reward, stress, and executive functions like decision making and self-control. DSM-5 notes that both amphetamine-type and cocaine-type stimulant use disorders can develop as quickly as 1 week (APA, 2013). Multiple factors influence whether and how rapidly a person will develop an SUD, including the substance itself; the genetic vulnerability of the user; and the amount, frequency, and duration of the misuse.
- **Tolerance:** A condition in which higher doses of a drug are required to produce the same effect as experienced initially; often leads to physical dependence.
- **Withdrawal:** A psychological and/or physical syndrome caused by the abrupt cessation of the use of a drug in an habituated individual.
- **Withdrawal management:** A process of allowing the body to clear a drug while the symptoms of withdrawal are managed; often the first step in an SUD treatment program.

* Definitions of all terms with an asterisk correspond closely to those in *Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health*. This resource provides a great deal of useful information about substance misuse and its impact on U.S. public health. The report is available online (<https://addiction.surgeongeneral.gov>).



Scope of the TIP

This TIP looks at stimulants derived from the coca plant (cocaine hydrochloride and its derivatives) and the synthetically produced amphetamines. Regarding amphetamines, the TIP focuses on MA—the major illicitly produced and misused drug in this group—in its various forms. Certainly, there are other stimulants that are more widely used (e.g., caffeine) or that produce major health and social problems (e.g., nicotine); however, discussion of these substances is beyond the scope of this document.

Although considered drugs of misuse, MA analogs are not included in this document. These analogs are compounds with MA-like molecular structures but not necessarily effects similar to MA. Sometimes called designer drugs, they include MDA (3,4-methylenedioxy-amphetamine) and MDMA (3,4-methylene-dioxymethamphetamine).

Current Stimulant Use in the United States

Stimulant epidemics of the 1980s and 1990s had a devastating impact on American society. The impact of illicit stimulant use affected international politics, the U.S. legal system, and the U.S. healthcare system.


As the end of the 20th century neared, the powerful psychostimulants cocaine and MA and their derivatives joined opioids and alcohol as primary targets in the efforts to combat SUDs and misuse of prescription stimulants. The pressing need to effectively address the stimulant epidemic and treat people with stimulant use disorders produced a tremendous amount of scientific and clinical research. The results of this research broadened our knowledge of the human brain and expanded our understanding of SUDs.

Recent statistics demonstrate the scope of stimulant use in the United States. For instance (Center for Behavioral Health Statistics and Quality [CBHSQ], 2020a):

- Among people age 26 and older, past-month cocaine use increased slightly from 1.3 million in 2016 to 1.5 million in 2017, and essentially remained level for the next 2 years.
- Past-year MA use among people ages 18 to 25 increased moderately from 2016 to 2017 (approximately 256,000 to 375,000), but then leveled out around 275,000 in 2018 and 2019.
- Past-year MA use among people age 26 and older increased each year, from 1.1 million in 2016 to 1.7 million in 2019.
- Past-year prescription stimulant misuse was steady among people age 26 and older from 2016 to 2019. However, among people ages 18 to 25, misuse has decreased, from about 2.5 million in 2016 and 2017 to 2 million in 2019.

Stimulant-involved overdose deaths in the United States have skyrocketed over the past 20 years. From 1999 to 2019, overdose fatalities from psychostimulants with misuse potential other than cocaine (e.g., MA) grew more than 29-fold, from 547 deaths in 1999 to 16,167 in 2019 (National Center for Health Statistics [NCHS], 2020; National Institute on Drug Abuse [NIDA], 2021a). In that same time, overdose deaths due to cocaine increased from 3,822 in 1999 to 15,883 in 2019 (NCHS, 2020; NIDA, 2021a).

More recently, overdose deaths involving cocaine increased by 26.5 percent from the 12 months ending in June 2019 to the 12 months ending in May 2020. Overdose deaths involving other psychostimulants (e.g., methamphetamine, prescription stimulants, amphetamines) are provisionally calculated to have increased by 34.8 percent across the same comparison periods (Centers for Disease Control and Prevention [CDC], 2020c).



These patterns appear to be strongly driven by the increasingly popular trend of combining cocaine or MA with synthetic opioids (e.g., fentanyl) or nonsynthetic opioids (e.g., heroin). Most MA in the United States is cultivated and produced in Mexico, whereas Colombia is the United States' main supplier of cocaine (although the Mexico-Southwest border is the primary port of entry into the United States; Drug Enforcement Administration [DEA], 2019, 2021). Increasing amounts of the MA produced by Mexican cartels and transported into the United States now contain fentanyl in varying amounts. Much of the stimulant product sold on the street currently includes fentanyl.

Like MA, cocaine is increasingly being combined with fentanyl (or with both heroin and fentanyl, in what is known as a super speedball) to help offset the steep decline individuals experience when a cocaine "high" subsides (DEA, 2019, 2021). Most cocaine is adulterated with fentanyl at the "retail" level and not the "wholesale" level—that is, after it enters the United States (DEA, 2019, 2021).


The connection of stimulant use to the opioid epidemic is very real and very dangerous:

- The State Unintentional Drug Overdose Reporting System found that, from January to June 2019, the most common stimulant in stimulant–opioid combinations leading to overdose death was cocaine (68.5% of cases), followed by MA (33.3%; O'Donnell et al., 2020).
- For both cocaine and MA, the number of overdose deaths also involving opioids has increased steadily since 2014. For cocaine, overdose deaths are primarily due to combinations with fentanyl or fentanyl analogs specifically (NIDA, 2021a).
- Data from the National Vital Statistics System found the percentage of cocaine-related overdose deaths also involving any opioid increased from almost 30 percent in 2000 to 63 percent in 2015 (McCall Jones et al., 2017).

Price and purity have likely played a role in the changing statistics on U.S. stimulant use, overdose, and fatalities. In 2018, the average purity of wholesale cocaine bricks analyzed by DEA's Cocaine Signature Program was 85 percent (DEA, 2019). In the first half of 2019, the average purity of MA was over 97 percent (DEA, 2021). From 2013 to 2017, the price of MA purchased in the United States decreased by more than 17 percent, from \$68 to \$56 per pure gram (DEA, 2019). Like MA, domestic purchases of cocaine also became less expensive from 2013 to 2017, falling from \$213 to \$153 per pure gram (DEA, 2019).

Also contributing to the increased lethality of MA is the shift toward production using phenyl-2-propanone as the chemical precursor to synthesis rather than ephedrine or pseudoephedrine. Using pseudoephedrine has been hindered somewhat by reduced access to sales of the over-the-counter product as a result of the Combat Methamphetamine Act of 2005 (see the text box "Legislative and Regulatory Milestones Since 2000"). The phenyl-2-propanone method bypasses the use of strictly controlled chemicals (i.e., ephedrine, pseudoephedrine) and yields a highly potent form of MA. More than 99 percent of MA samples analyzed in the first half of 2019 by the DEA Methamphetamine Profiling Program were manufactured using the phenyl-2-propanone method (DEA, 2021).

The breakdown of stimulant overdose patterns by race/ethnicity underscores differential effects among people of color. In 2019, the highest total number of psychostimulant-related deaths by race occurred among Whites (13,987), but the highest crude death rate by race was among American Indian/Alaska Native populations, at 8.1 deaths per 100,000 people (NCHS, 2020). (Crude death rates are a measure of the number of deaths within a given population during a specified period.) For cocaine, the highest crude death rate by race was among Blacks/African Americans, at 10.9 deaths per 100,000 people—more than twice that of the next-highest crude death rate (4.3 deaths per 100,000 Whites) and more than 4 times that of American Indian/Alaska Native populations (2.5 deaths per 100,000; NCHS, 2020).



ANNUAL HOSPITAL COSTS related to amphetamines **INCREASED NEARLY 500%** between 2003 and 2015—from **\$436 million to \$2.17 billion** (Winkelman et al., 2018).

Treatment for stimulant use disorders has been increasing recently. From 2015 to 2017, treatment admissions (i.e., the formal acceptance of a client into SUD treatment) for crack cocaine increased by 11 percent, for nonsmoked cocaine by 37 percent, for amphetamines by 41 percent, and for other stimulants by 62 percent (CBHSQ, 2020b).

But unmet treatment need is pervasive across SUDs broadly, with data from the Substance Abuse and Mental Health Services Administration's (SAMHSA) 2019 National Survey on Drug Use and Health indicating that only 10 percent of people age 12 and older who had a past-year SUD received any SUD treatment, and only 1 percent received treatment at an SUD specialty facility (CBHSQ, 2020a).

Treatment dropout is also a problem. A meta-analysis of 151 studies looking at SUD treatment rates (Lappan et al., 2020) found that the overall treatment dropout rate across all SUDs is 30.4 percent. By comparison, the treatment dropout rate is 53.5 percent for MA and 48.7 percent for cocaine (Lappan et al., 2020).

Cocaine

Both the increase in cultivation and production of cocaine from Colombia—which supplies more than 90 percent of U.S. cocaine seized by DEA—as well as the increased purity of cocaine entering the United States have made cocaine use, cocaine use disorder, and fatal overdose growing concerns over the past two decades (DEA, 2017; Kerridge et al., 2019). The prevalence of cocaine use among U.S. adults in 2019 was 5.5 million for past-year use, 2 million for past-month use, and 1 million for a stimulant use disorder involving cocaine (CBHSQ, 2020a).

The 2020 Monitoring the Future survey found that 2.9 percent of 12th graders reported past-year use of cocaine (University of Michigan, 2020). Cocaine use among adolescents and young adults is particularly worrisome given potential long-term effects on neurodevelopment, cardiovascular functioning, and psychosocial functioning, and the association between cocaine use and polysubstance use (Ryan, 2019).

In 2019, almost 65 percent of U.S. adults with cocaine use had a history of any mental illness, 36 percent had a serious mental illness, and 31 percent had at least one major depressive episode (CBHSQ, 2020a).

Methamphetamine

The prevalence of MA use among people age 12 and older in the United States in 2019 was 2 million for past-year use, 1.2 million for past-month use, and 1 million for a stimulant use disorder involving MA (CBHSQ, 2020a). From 2015 to 2018, approximately 1 million men and almost 600,000 women took part in past-year MA use (C. M. Jones et al., 2020). Of those adults with past-year MA use, 53 percent met criteria from the fourth edition of DSM for MA use disorder (C. M. Jones et al., 2020). The number of people age 26 and older with past-year MA use rose more than 50 percent from 2016 to 2019 (1.1 million in 2016 to 1.7 million in 2019; CBHSQ, 2020a).

MA use frequently co-occurs with other substance use and with a mental disorder (C. M. Jones et al., 2020). Among people 12 and older with past-year MA use in 2019, an estimated 68 percent engaged in past-year cannabis use, 43 percent in past-year opioid misuse, and 32 percent in past-year cocaine use; 24 percent experienced a past-year major depressive episode. Additionally, among adults who used MA in 2019, an estimated 27 percent had past-year serious mental illness (CBHSQ, 2020a).

Prescription Stimulant Misuse

Stimulant medication is FDA approved for treating attention deficit hyperactivity disorder (ADHD) and narcolepsy (a disorder of extreme sleepiness). Commonly prescribed stimulants include dextroamphetamine, dextroamphetamine/amphetamine combination product, and methylphenidate.

The prescribing of these medications has been increasing. National prescription stimulant dispensing rates grew significantly from 2014 to 2019, from 5.6 prescriptions per 100 persons to 6.1 per 100 persons, with the growth attributable in large part to increases among women and adults age 20 and older (Board et al., 2020). Total usage of prescription amphetamine, methylphenidate, lisdexamfetamine, and prescription MA, including extended-release formulations, doubled from 2006 to 2016 (Piper et al., 2018; Sembower et al., 2013). Further, from 2007 to 2011, the prevalence of children taking medication for ADHD increased by 28 percent, from 4.8 to 6.1 percent (Visser et al., 2014). Between 2013 and 2015, CDC reported a 344-percent increase in ADHD prescription medication claims by privately insured women ages 15 to 44 (K. N. Anderson et al., 2018).

Rates of nonmedical prescription stimulant use also are concerning. In 2019, almost 4.5 million adults in the United States reported past-year misuse, 1.4 million reported past-month misuse, and 492,000 met criteria for a stimulant use disorder involving prescription stimulant misuse (CBHSQ, 2020a).


Data suggest diversion of stimulant medication is increasing among U.S. adolescents and may occur out of a desire to enhance academic performance (Colaneri et al., 2017). Additionally, among young adults, anywhere from 5 to 35 percent of college students reportedly misuse prescription stimulants not just for enhanced neurocognitive performance but for euphoric effects or weight control as well (Benson et al., 2015; Kilwein et al., 2016; Weyandt et al., 2013, 2016; Wilens et al., 2016).

Prescribers can help limit diversion of stimulants by adhering to DSM-5 criteria when diagnosing ADHD so that the medication is appropriately prescribed. When a prescription is written, the prescriber should cross-reference the prescription information with data available in state-run prescription drug monitoring programs. Prescribers can also help prevent stimulant medication misuse through numerous strategies, including (Colaneri et al., 2017):

- Using medication contracts.
- Educating patients, especially high school and college students who are diagnosed with ADHD, about the danger of sharing their medication with friends and the legal implications of this.
- Limiting prescriptions to a smaller number of pills.
- Implementing pill counts.
- Prescribing long-acting instead of immediate-release formulations.

Additionally, because overdiagnosis and incorrect diagnosis can lead to inappropriate prescribing, primary care providers should not diagnose ADHD themselves. Rather, they should refer patients to an appropriate mental health service professional (such as a psychiatrist or psychologist) for evaluation.

Prescribing nonstimulant medications for ADHD is another option that is particularly relevant for patients with a stimulant use disorder and co-occurring ADHD who want to pursue abstinence. Atomoxetine is a norepinephrine reuptake inhibitor that is not a DEA-controlled substance because it has very low misuse/stimulant use disorder potential (Clemow & Walker, 2014). Guanfacine and clonidine are alpha2-adrenergic receptor agonists that also have demonstrated good efficacy in reducing ADHD symptoms but have low misuse potential (Clemow & Walker, 2014). To learn more about managing ADHD in people with co-occurring stimulant use disorder, see Chapter 6.



LEGISLATIVE AND REGULATORY MILESTONES SINCE 2000

The statutory and regulatory landscape of SUD prevention and treatment has changed since the original publication of this TIP in 1999. Here are important statutory and regulatory developments related to the topics in this TIP:

- **The Drug Addiction Treatment Act of 2000:** This legislation, as amended, allows healthcare professionals who meet certain qualifications to offer Food and Drug Administration (FDA)-approved narcotic medication treatment for opioid use disorder in settings other than opioid treatment programs. (At the time of this publication, buprenorphine is the only approved medication that meets the provisions of the act.) This is relevant for patients with stimulant use disorder who are also using opioids and wish to initiate buprenorphine treatment. For the law as originally enacted, see Title XXXV here: www.govinfo.gov/content/pkg/PLAW-106publ310/pdf/PLAW-106publ310.pdf. For later statutory changes expanding buprenorphine prescribing, see www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines.
- **The Combat Methamphetamine Epidemic Act of 2005:** This act requires purchasers to show a photographic identification card or other acceptable document issued by a state or the federal government when buying over-the-counter cold medicines containing ingredients that are commonly used to make MA, such as pseudoephedrine. It also limits the amount of these products that can be purchased at one time and tracks purchasers. Read more about the act at www.deadiversion.usdoj.gov/meth/.
- **Fair Sentencing Act of 2010:** This act reduced the 5-to-10-year “mandatory minimum” prison sentence for possession of low-level crack cocaine. It also removed the mandatory minimum for simple possession of cocaine. Read more about the act at www.ussc.gov/research/congressional-reports/2015-report-congress-impact-fair-sentencing-act-2010.
- **The 21st Century Cures Act of 2016:** This act was passed to help increase the speed and efficiency of the discovery, development, and delivery of medical cures. It provided U.S. research and healthcare delivery institutions, like FDA and the National Institutes of Health, with funding to improve clinical trials, enhance data sharing, increase the recruitment of participants in clinical trials, and launch innovative research projects. It also established the State Targeted Response to the Opioid Crisis grant program. For the text of the act, see www.congress.gov/114/plaws/publ255/PLAW-114publ255.pdf.
- **The Comprehensive Addiction and Recovery Act (CARA) of 2016:** This legislation authorizes grant programs designed to expand SUD (especially opioid use disorder) prevention, education, treatment, and recovery efforts. The act includes provisions explicitly aimed at supporting such efforts in communities facing sudden increases in MA use. For the text of the act, see www.congress.gov/bill/114th-congress/senate-bill/524/text.
- **Confidentiality of Substance Use Disorder Patient Records (42 CFR Part 2):** Changes to these regulations—which pertain to patient records in federally assisted SUD treatment programs—were made in response to the opioid epidemic. For a summary of these revisions, review SAMHSA’s 42 CFR Part 2 Revised Rule Fact Sheet at www.hhs.gov/about/news/2020/07/13/fact-sheet-samhsa-42-cfr-part-2-revised-rule.html.

Importance of Science in Building Future Treatments


The original TIP's consensus panel believed that scientifically derived knowledge should serve as the foundation of treatment for stimulant use disorders. Findings from basic and clinical research efforts funded by NIDA, as well as other government and private institutions, have given treatment providers a set of strategies and tools to assist people with stimulant use disorders.

At this time, the approaches with the greatest empirical support combine psychosocial and behavioral strategies delivered in outpatient settings (e.g., contingency management, cognitive-behavioral therapy/relapse prevention). Emerging treatment techniques include exercise and mindfulness meditation. As knowledge of stimulants and brain functioning rapidly increases, thanks to active research funded by federal agencies and private foundations, other new approaches should soon be forthcoming. The development of pharmacotherapies for the treatment of stimulant use disorders remains a major priority of research efforts, and these efforts will likely provide some important new options in the near future.

Summary

Stimulant use and related deaths in the United States are growing problems that are intertwined with the current opioid epidemic. Stimulant use disorders have direct effects on the health and functioning of people with these disorders as well as secondary effects on others around them. This is partly what makes treatment so critical. SUD treatments and services not only help individuals with stimulant use disorders, but also benefit their entire support system and surrounding environment (e.g., family, friends, workplace, neighborhood). Treatment rates are lower than needed to keep pace with the number of individuals using stimulants and developing stimulant use disorders each year. New knowledge about how these substances influence the basic electrical and chemical activity of the human brain has allowed a better understanding of how and why stimulants affect human behavior, and this knowledge has rapidly influenced the development of new treatment efforts. This TIP provides an overview of:

1. The new knowledge about stimulants.
2. The treatment efforts to address stimulant use disorders.
3. Other clinical, medical, and social interventions developed in response to these disorders.




Chapter 2—How Stimulants Affect the Brain and Behavior

KEY MESSAGES

- A stimulant use disorder changes a person's brain in two major ways. One is neurotoxic (by affecting brain processes such as memory, learning, and other cognitive functions). The other way is by triggering the addiction process, such as by acting on the brain's reward system or through the development of craving. This information is critical for clinicians to understand because it explains the course of symptoms and recovery and underscores how difficult it is to quit using/misusing substances without interventions.
- A host of harmful effects can occur from acute and chronic cocaine or methamphetamine use, with some evidence from human studies suggesting that long-term stimulant exposure can cause persistent damage to the brain.
- The neurobiology of stimulant use disorders underscores the biologic aspects of substance use disorders as a chronic, relapsing medical illness. Understanding the changes in the brain that occur as someone becomes addicted to stimulants, experiences withdrawal, or stops using stimulants can also help guide clinicians in their approaches to treatment as well as help them understand behaviors and moods that a patient may experience throughout recovery.

Over the past several decades, research on substances of misuse has vastly improved understanding of human behavior and physiology and the nature of substance use disorders (SUDs). Basic neurobiologic research has enhanced understanding of the biologic and genetic causes of SUDs. These discoveries have helped establish SUD as a biologic brain disease that is chronic and relapsing in nature (National Institute on Drug Abuse [NIDA], 2018c; Volkow et al., 2019). By mapping the neural pathways of pleasure and pain through the human brain, investigators are beginning to understand how psychoactive substances, including stimulants, interact with various cells and neurochemicals in the brain.

This new information has also improved understanding of appropriate treatment approaches for different SUDs. This chapter describes the effects that acute and chronic cocaine and methamphetamine (MA) use, and prescription stimulant misuse, have on a person's brain and behavior. The chapter also discusses how to assess for and diagnose stimulant use disorders. Knowledge of the neurobiologic effects of stimulants will give clinicians greater insight into people who use stimulants, how to detect a stimulant use disorder in an individual, and why the treatment approaches described in Chapter 4 are effective.



Substance Use Disorders

SUDs are complex phenomena with numerous psychological, social, familial, emotional, and systemic contributors. SUDs often co-occur, and people with stimulant use disorders often also use or misuse other substances (Timko et al., 2018). However, at the core, SUDs involve a biologic process: the effects of repeated exposure to an agent (a substance) on a biologic substrate (the brain) over time (MacNicol, 2017; Volkow et al., 2019). Ultimately, adaptations that substance exposure elicits in individual neurons alter the functioning of those neurons, which in turn alters the functioning of the neural circuits and networks in which those neurons operate. This eventually leads to the complex phenomena that characterize SUDs (MacNicol, 2017).

Chronic substance use results in a complex set of physiological and neurologic adaptations. These adaptations are the body's attempt to adjust to or compensate for the intermittent or chronic presence of substances. Repeated exposure to a substance can also lead to adaptations in the reward circuitry that oppose and/or neutralize the substance's effects (i.e., counteradaptation). See Exhibit 2.1 for the parts of the brain that make up the reward circuitry. SUD-related brain activity can be characterized in three stages:

1. Acute intoxication/binge
2. Withdrawal/negative affect stage
3. Anticipation/craving


Each stage has its own complicated and intricate neurocircuitry that continues to reinforce the seeking and use of a specific substance (Koob & Volkow, 2016). There are more than 18 systems of neuromodulation involved in the perpetuation of the three stages of SUDs in the brain; three important structures and regions are the basal ganglia, the amygdala, and the prefrontal cortex (Koob & Volkow, 2016).

A SIMPLE WAY OF THINKING ABOUT SUDS

A helpful way to think about SUDs and the processes within the brain that go awry is to think of the brain as having a “stop” system and a “go” system (Office of the Surgeon General, 2016). The “go” system is the reward-seeking component that drives an individual to make decisions and achieve goals. The “stop” system inhibits the “go” system. In SUDs, the brain’s “go” system is activated when an individual seeks substances in response to a substance-related cue in the environment. The “go” system also helps drive habitual behavior, which too can play a role in substance seeking. But the “stop” is ineffective in controlling these behaviors, because substance-related changes in the brain can decrease the “stop” system’s activity and increase the “go” system’s activity. Another way of thinking about this is that having an SUD is like driving a car without brakes (NIDAnews, 2014), which helps explain why people with SUDs cannot easily suppress their “go” system to “just stop” using or misusing substances.

With increasing use and development of tolerance to the effects of a substance, people will need to increase the amount taken to produce the desired effects. As substance use increases, so does disruption of executive function and of the reward and stress pathways. (The stress pathway comprises the various neurobiologic mechanisms invoked in response to stressful stimuli, such as the “fight or flight” response triggered by the hypothalamic–pituitary–adrenal axis.) These disruptions result in patients continuing to use and seek substances despite adverse consequences—the very definition of an SUD (Koob & Volkow, 2016).

EXHIBIT 2.1. Brain Structures Involved in the Reward System



Source: From Telzer (2016). Adapted with permission from Elsevier.


HOW TO UNDERSTAND A PERSON'S STRUGGLE WITH SUDS

Over the past three centuries, many theories evolved to explain why some people can use a substance with little risk, whereas others have difficulty controlling their use. The most widely accepted term for the combination of factors and processes contributing to the development of an SUD is **biopsychosocial**. This term includes the influence that genetic/biologic, psychological, and sociocultural factors have on short- and long-term effects of substance use. In the biopsychosocial model, all of these components are taken into account when working to prevent and treat SUDs (Skewes & González, 2013).

To understand the specific contribution of biology compared with the contribution of a person's environment, researchers look to monozygotic (i.e., identical) and dizygotic (i.e., nonidentical) twin studies. Twin studies often examine siblings who were separated at birth versus those who both remained in their family of origin. These studies point to the influence genes have on the development of SUDs (Ducci & Goldman, 2012). Although these genetic/biologic factors are clearly important, gender, development, environment, and culture also play a determining role.

Researchers' understanding of substance use is continually evolving and thus so are the models society uses to explain why some individuals can use substances without harm and others develop SUDs. The predominant model from the 18th and 19th centuries focused on morals. This "moral model" defined an SUD as a sin driven by the person's desires and wrongful choices. This model led to harsh treatment of people with SUDs, and its effects can still be seen in the stigma people with SUDs still encounter.

Continued on next page

*Continued*

Stigma and associated feelings of shame persist despite the fact that, by the mid-1900s, the disease model of SUDs had emerged, supported by research findings that there was no one type of person predisposed to alcohol use disorder. Additionally, advances in brain imaging allowed researchers to visualize neurologic changes in specific brain regions and neurotransmitters, highlighting the influence and primary importance of the reward systems involved.

These biologically driven findings led to the current understanding of SUDs as brain diseases, propelling clinical researchers to develop medicines to counter the physiologic effects on the brain (e.g., pharmacotherapies like methadone and naltrexone).

Although the basic neurologic structures are fairly consistent across humans, there is a considerable amount of neuroplasticity and researchers learned that the brain is both static and dynamic throughout the lifespan. In the 1970s, the social learning model emerged, highlighting the influence of social interactions and behaviors on SUDs (Giovazolias & Themeli, 2014). In this model, any person using a substance could become dependent through the influence of conditioning, modeling others, thinking about substance use, and still using despite the negative consequences.

An offshoot of the social learning model is the sociocultural model, which describes the effects of society on the individual's behaviors and takes into account differences across cultures, races, and ethnicities. This model aligns well with our newer understanding of social determinants of health, including food and housing insecurities, adverse childhood experiences, and generational trauma—all of which may be associated with more prevalent substance use.

Current SUD research suggests that clinicians and researchers need to take into account both physiologic components (e.g., genetics, neurobiology, neuroplasticity) and biopsychosocial aspects of the human experience (e.g., culture, environment and socialization, human development and behaviors throughout the lifespan) to develop a full conceptualization of the origin and severity of SUDs.

Neurobiology

The human nervous system is an elegant communication system, and the brain is the control center. The brain processes sensory information from throughout the body, guides muscle movement and locomotion, regulates a multitude of bodily functions, forms thoughts and feelings, modulates perception and moods, and essentially controls all behavior. Neurotransmitters (chemicals that transfer information between neurons and help neurons communicate with one another) also play a key role in the neurobiology of SUDs.


The Reward System or Positive Reinforcement

The brain circuit that is considered essential to neurologic reinforcement is called the **limbic reward system** (also called the **dopamine reward system** or the **brain reward system**).

This neural circuit extends across the **ventral tegmental area**, the **nucleus accumbens**, and the **prefrontal cortex**.

Substances of misuse—including stimulants—affect the reward system (Volkow et al., 2019). Normal functioning of the brain's circuitry results in inhibition and stimulation of neurotransmitters at multiple sites in the brain's reward systems. However, neuroadaptation and neuroplasticity that occur when substances are present can result in multiple neurotransmitters disrupting this normal circuitry, resulting in prolonged phases of withdrawal/negative affect and anticipation/craving (Koob & Volkow, 2016).

The neurotransmitter dopamine, which helps to regulate the feelings of pleasure (euphoria and satisfaction), is both directly and indirectly affected by stimulants (Volkow et al., 2019). Dopamine also



plays an important role in the control of movement, cognition, motivation, and reward (Bromberg-Martin et al., 2010; Volkow et al., 2019). In addition, stimulant use causes the brain to release norepinephrine, which helps regulate mood, attention, learning, memory, and arousal and may play a role in substance withdrawal (Office of the Surgeon General, 2016). The neurotransmitter serotonin affects reinforcement, motivation, learning, and memory, and may play a role in SUDs by making people more susceptible to compulsive (rather than controlled) substance use, especially people with genetic vulnerabilities to SUDs (Müller & Homberg, 2015).

Activities such as eating, drinking, and sex activate the reward system, inducing considerable communication among this structure's neurons. This internal communication leads to the release of dopamine. But substance use causes a surge of dopamine release that is far beyond that of natural activities, like eating and sex. The released dopamine produces immediate, but short-lived, feelings of pleasure and elation.

As dopamine levels subside, so do the feelings of pleasure. But if the activity is repeated, then dopamine is again released, and more feelings of pleasure and euphoria are produced. The release of dopamine and the resulting pleasurable feelings positively reinforce such activities and motivate the repetition of these activities. Moreover, with substance use, the person needs more and more of the substance to achieve the same level of pleasure.

Dopamine is believed to play an important role in the reinforcement of and motivation for repetitive actions (Daw & Tobler, 2013; Nutt et al., 2015; Volkow et al., 2019). An increasing amount of scientific evidence suggests that neuroadaptations to the reward and stress systems play a considerable role in the development of compulsive use behaviors (Koob & Volkow, 2016).

When the nucleus accumbens is functioning normally, communication among its neurons occurs in a consistent and predictable manner (Koob & Volkow, 2016). First, an electrical signal within a stimulated neuron reaches its point of connection

(i.e., the synapse) with the target (postsynaptic) neuron. The electrical signal in the transmitting (presynaptic) neuron triggers the release of dopamine into the synaptic gap (Koob & Volkow, 2016). Dopamine travels across the synaptic gap until it reaches the postsynaptic neuron. It then binds to the postsynaptic neuron's dopamine-specific receptors. The binding of dopamine to the receptor has an excitatory effect that generates an internal electrical signal within this neuron. However, not all of the released dopamine binds to the target neuron's receptors. Extra dopamine may be chemically deactivated, or it may be quickly reabsorbed by the presynaptic neuron through a system called the dopamine reuptake transporter (see Exhibit 2.2).

The postsynaptic neuron receives messages in the form of neurotransmitters released from the presynaptic neuron, resulting in depolarization or hyperpolarization of the postsynaptic neuron membrane. If the membrane is depolarized to a certain degree, an action potential occurs that causes the neuron to release a neurotransmitter (i.e., to "send a message").

To learn more about the reward circuit in stimulant use disorders, see the NIDA video "The Reward Circuit: How the Brain Responds to Cocaine" (<https://www.drugabuse.gov/videos/reward-circuit-how-brain-responds-to-cocaine>).

The Stress System or Negative Reinforcement

In addition to positive reinforcement through the brain's reward system, negative reinforcement can play a key role in the development and maintenance of chronic, compulsive substance use (Wise & Koob, 2014). The motivation to use a substance to avoid discomfort is an example of negative reinforcement. This motivation to continue using a substance occurs in the withdrawal/negative affect stage of substance use and also in the anticipation/craving stage.





EXHIBIT 2.2. Normal Dopamine Transmission




As people experience negative withdrawal symptoms from not using a substance, their brain circuitry causes further dysregulation of executive function and other cognitive processes. This dysregulation creates negative effects in the absence of the substance, further driving the precontemplation/craving phase to reinforce the compulsive seeking and taking of the substance (Koob & Volkow, 2016).

Experimental evidence supports the theory that stimulants and other commonly misused substances imitate, facilitate, or block the neurotransmitters (especially dopamine) involved in brain reinforcement systems (Ashok et al., 2017; dela Peña et al., 2015; Nutt et al., 2015; Volkow et al., 2019). Negative reinforcement

through overactivation of the stress system or the anti-reward system could also play a role in the perpetuation of chronic recurrent use to alleviate negative effects (Koob & Volkow, 2016).

Drug Craving and Memory

The degree to which learning and memory sustain the addictive process has also been addressed. Researchers believe that each time a neurotransmitter like dopamine floods across a synapse, circuits that trigger thoughts and memories and that motivate action become more strongly activated in the brain. Moreover, activation of the reward system creates a very powerful association between the euphoric and other rewarding effects of the substance and whatever



people, objects, or places the individual is exposed to at the time; these people, objects, or places then can become cues for substance use (Office of the Surgeon General, 2016).

Craving, a central aspect of SUDs, is a very strong learned response with powerful motivational properties often associated with specific memories (i.e., conditioned cues and triggers; Carmack et al., 2017). Cues—any stimuli (e.g., drug paraphernalia, moods, friends who use substances, locations associated with substance use) repeatedly paired with substance use over the course of a patient's SUD—can become so strongly associated with the substance's effects that the associated (conditioned) stimuli can later trigger arousal and an intense desire for the substance and lead to recurrent use (Carmack et al., 2017). High recurrence rates are common in people with stimulant use disorders even after treatment (Brecht & Herbeck, 2014).

Brain imaging studies have shown that cue-induced drug craving may be linked to distinct brain systems involved in memory (Moreno-Rius & Miquel, 2017; Perry et al., 2014). Brain structures involved in memory and learning, including the dorsolateral prefrontal cortex, amygdala, and cerebellum, have been linked to cue-induced craving (Moreno-Rius & Miquel, 2017; Sinha, 2013). A network of these brain regions integrates emotional and cognitive aspects of memory and triggers craving when it reacts to cues and memories. These cues and memories also play an important role in reinforcing substance use (Carmack et al., 2017). In contrast, negative experiences (e.g., violence, trauma, paranoia) that occur during acute intoxication do not seem to reinforce avoidance of intoxication.

Most SUD treatment approaches recognize the power of these factors in triggering recurrent use and warn patients to avoid everything previously associated with their substance use. Treatment approaches that address these learning and memory issues of SUDs may prove effective. For example, cue exposure therapy uses extinction (i.e., breaking the individual's association


between the trigger or cue—like seeing drug paraphernalia—and the conditioned response—such as experiencing feelings of craving) to help decrease physiologic reactions to triggers and decrease cravings (Carmack et al., 2017; Torregrossa & Taylor, 2013).

Researchers have examined other methods of similarly reducing physiologic responses to triggers and thereby reducing craving, such as inhibiting memory reconsolidation (i.e., the process of stabilizing newly formed memories so they can be stored long term) and using pharmacologic agents (e.g., propranolol) to enhance the extinction process used in cue exposure therapy (Torregrossa & Taylor, 2013). People with SUDs may further benefit from cue exposure therapy that is combined with other psychosocial interventions, like cognitive therapy and motivational enhancement (Kaplan et al., 2011).

Role of Technologies

The development of noninvasive brain imaging (e.g., positron emission tomography [PET] scans) has created a powerful new tool for demonstrating not only the short-term effects of substance use but also the longer term consequences of chronic substance use and SUDs. These tools have allowed researchers to go where they previously could not—literally into a living human brain. However, this research is still maturing, and many questions remain about whether and how these technologies might inform clinicians' care of people with stimulant use disorders.

Such noninvasive techniques can depict higher or lower activity levels of different brain areas by measuring metabolic activity (e.g., glucose use; Fakhoury, 2014). They can identify substance-induced structural changes and physiologic adaptations (Fakhoury, 2014). Through a combination of techniques, researchers and clinicians can observe the altered processing of information in various circuits as the brain responds to substance use.



Using noninvasive imaging techniques, investigators have been able to identify brain structures involved in craving, map the emotions of people who use substances, and plot the neurobiologic basis of substance-induced euphoria. For example, researchers have used functional magnetic resonance imaging to predict substance use relapse and maintenance of abstinence (S. J. Moeller & Paulus, 2018). Additional neuroimaging studies have demonstrated significant changes in gray matter and in neurochemistry and have also predicted long-term effects of substance use and potential for recurrent use (S. J. Moeller & Paulus, 2018).

PET has revealed subtle alterations in the dopamine receptors in the brains of people who use stimulants (Solingapuram Sai et al., 2019). A review of some PET studies has demonstrated not just reductions in dopamine receptor availability and sensitivity associated with cocaine and MA use, but also increased dopamine release (Wiers et al., 2016). Combining PET with the radiotracer [^{18}F]-fluorodeoxyglucose—which is used to visualize brain glucose metabolism—has helped researchers understand changes in the brain’s metabolic activity associated with craving, alterations in cognition, self-regulation, and intoxication (Wiers et al., 2016).


PET imaging has also provided insight into stimulant-related effects on neurofunction such as identifying inflammation in the brain, understanding the influence of cocaine on mu-opioid receptor binding, and pinpointing increases in norepinephrine in the synapses due to blockage of its reuptake (Wiers et al., 2016). Single photon emission computerized tomography—a form of PET that uses a different type of radiotracer—may prove to be a useful diagnostic and classification tool (e.g., differentiating people at high risk of recurrent use from those who are not).

Structural magnetic resonance imaging studies of people with MA use have shown clear gray matter deficits in cortical areas (i.e., frontal, insular, cingulate, temporal, and occipital cortices) and in the hippocampus, along with an increase

in volume in the parietal lobe and the striatum (Hall et al., 2015; Jan et al., 2012). White matter enhancement appears to occur in the temporal and occipital lobes, accompanied by widespread white matter hyperintensities and aberrations in the corpus callosum (Jan et al., 2012). Structural changes documented in people with cocaine and amphetamine use include reduced gray matter in the insula, ventromedial prefrontal cortex, inferior frontal gyrus, pregenual anterior cingulate gyrus, and anterior thalamus (Ersche et al., 2013; Hall et al., 2015). Research is ongoing to better understand what these patterns mean and how structural deficits and changes affect substance use behaviors and outcomes.

Imaging research is also providing important evidence about changes that can take place in the brain with abstinence and SUD treatment. For instance, exercise training for people in treatment for MA use disorder (and who were abstinent) was associated with recovery of certain striatal dopamine receptors that are known to become deficient with MA exposure—although it should be noted that abstinence plus education did not produce these benefits (C. L. Robertson et al., 2016). Nonetheless, such research suggests that healing in the brain can occur, providing additional evidence for the importance of promoting abstinence and recovery.

Although mapping brain activity during stimulant use and withdrawal may allow researchers to further document substance-induced neuropsychological impairments, not much of this research has been conducted in humans. Animal models suggest stimulant withdrawal is accompanied by a reduction in modularity—the ability of independent and functionally separate networks within the brain to interact with one another, somewhat like an electric circuit board with independent circuits that can connect to one another (Kalvar & Medaglia, 2018). Reduced modularity appears to occur in thalamic regions for MA and in a combination of midbrain-cortico-thalamic-hypothalamic-amygdalar brain regions for cocaine (Kimbrough et al., 2019).



The continuing development and application of new technologies such as noninvasive brain imaging will allow researchers to improve their understanding of how stimulants affect the human brain. Greater understanding of the underlying neuronal impairments of stimulant use will aid in the development of new and more effective treatment approaches.

Stimulant Use and the Brain

To better understand underlying drivers for substance use, it is important to learn the effects of any particular substance on a given person. For instance, someone with long-term stimulant use who is taking a stimulant and an opioid at the same time will be affected differently by that stimulant than someone taking a stimulant alone and for the first time. How stimulants affect individuals (both universal effects as well as person-specific effects) can provide helpful information to providers to assess, treat, and prevent recurrent use of the substance (Volkow et al., 2017).

Once a substance enters the bloodstream, it is transported throughout the body to various organs and organ systems, including the brain. To enter the brain, a substance's molecules must first get through its chemical protection system, which consists mainly of the blood–brain barrier. Tight cell-wall junctions and a layer of cells around the blood vessels keep large or electrically charged molecules from entering the brain. However, small neutral molecules like those of cocaine and MA easily pass through the blood–brain barrier and enter the brain (Kousik et al., 2012; Turowski & Kenny, 2015). Once inside the brain, substances begin to exert psychoactive effects.

Stimulants' Mechanisms of Action


On a short-term basis, stimulants exert their effects by disrupting or modifying the normal communication that occurs among brain neurons and brain circuits. Cocaine and MA have both been shown to disrupt the dopamine neurotransmitter system—cocaine indirectly and MA both directly and indirectly (Ashok et al., 2017). Both cocaine and MA can inhibit the reuptake and release of dopamine by the presynaptic neuron, resulting in excess dopamine in the synaptic gap.

The two common forms of prescription stimulants—methylphenidate and amphetamine—affect the dopamine system differently, but, like cocaine and MA, both result in increased extracellular dopamine. Methylphenidate inhibits the reuptake of dopamine, as does amphetamine; but amphetamine also increases the amount of dopamine initially released into the synaptic gap (Yanofski, 2011).

Whereas the mechanism of action of prescription stimulants is not drastically different from that of cocaine and MA, differences in effects can occur based on who is taking the substance (e.g., someone with attention deficit hyperactivity disorder [ADHD] versus someone without it), the dose taken, and how it is administered. These differences influence whether the prescription stimulant is a helpful therapy or a drug that can change the brain at the cellular and structural levels. Specifically, if a person has ADHD and takes a prescription stimulant, the medication is provided at a dose that increases dopamine to a level that provides relief from ADHD. When taken as directed (i.e., orally at the prescribed dosage and according to schedule), it provides a constant blood level of the medication. People with ADHD will feel more focused and productive as a result. But when MA, cocaine, or prescription stimulants are injected or smoked (or, in the case of medications, taken in higher-than-prescribed amounts or taken by people without ADHD), they can lead to brain changes and stimulant use disorder.

The use of stimulants increases the amount of available dopamine in the brain (Paulus & Stewart, 2020). High levels of available dopamine in the brain generally enhance mood and increase body movement (i.e., motor activity) and motivation, but too much dopamine may produce symptoms that approximate positive symptoms of schizophrenia (e.g., delusions, hallucinations, paranoia; Kesby et al., 2018; Klein et al., 2019). With cocaine, the effects are generally short-lived, whereas with MA, the duration of effect is much longer.

As the stimulant level in the brain decreases, the dopamine levels subside to normal, and the pleasurable feelings dwindle. With repeated



stimulant use, dopamine stores in the brain become temporarily depleted (Ashok et al., 2017), resulting in the depressive and exhaustive symptoms associated with stimulant withdrawal.

Although the neurochemical pathways of chronic stimulant use disorders are not definitively established, a few researchers have found evidence of changes in the structure and function of brain neurons after chronic stimulant use in humans. Some researchers propose that the changes may come from dopamine depletion, changes in neurotransmitter receptors or other structures, or changes in cellular components or other brain messenger pathways that could cause the changes in mood, behavior (e.g., compulsivity, decision making), and cognitive function associated with chronic stimulant misuse (Ashok et al., 2017; Jan et al., 2012). (The medical aspects of stimulant use disorders are discussed in Chapter 3.)

General Effects of Stimulants

Stimulants affect the normal functioning of the dopamine neurotransmitter system (Volkow et al., 2019). Stimulants appear to increase the brain's levels of free dopamine (Ashok et al., 2017; dela Peña et al., 2015; MacNicol, 2017; Volkow et al., 2019). The higher the substance dose, the greater the individual's feelings of wakefulness, mania, and euphoria. As the dopamine levels and pleasurable feelings subside, the individual experiences an intense desire to replicate the feelings of pleasure by administering another dose of the substance. As with substance use generally, this tendency toward repeated administration is characteristic of stimulant use disorders and underlies most of the other effects of stimulants, as well as most other addictive substances.


Half-lives of stimulants vary by drug. Cocaine, being naturally derived, has a much shorter half-life (around 60 minutes), whereas MA, being synthetic, has a half-life of around 10 hours (Coe et al., 2018; Cruickshank & Dyer, 2009). The half-lives of prescription stimulants also vary by drug and

by formulation (e.g., short-acting versus long-acting). For example, short-acting prescription amphetamine has a half-life of approximately 9 hours, whereas the long-acting formulation has a half-life in the range of 10 to 13 hours (Pradeep & Standeven, 2019).

Continued use often leads to adverse consequences, which may include neuropsychologic impairment, mental health issues, and diminished physical health. Work performance and social and family relations can be adversely affected, and the risk of arrest and criminal/legal involvement increases (McKetin et al., 2020).

It is important to note that in small and measured doses, stimulants may serve a clinical purpose to heighten wakefulness, help focus attention, and enhance cognition (see Exhibit 2.3). This could explain why some people who misuse prescription stimulants—especially adolescents in high school and young adults in college—often do so to improve their concentration and alertness, which they perceive as helping with their studying and academic performance (Clemow & Walker, 2014; Weyandt et al., 2018). Increasing doses, higher potency, and more frequent use increase psychostimulation and may eventually result in the cognitive impairments often correlated with stimulant use disorder (Wood et al., 2014). In very high doses, stimulant use can lead to serious medical complications, including coma and circulatory collapse, or even death (Wood et al., 2014).

For patients with a stimulant use disorder, impairments in the brain's reward systems that lead to problems with cognition and neuropsychiatric functioning may persist even after cessation of stimulant use (Taylor et al., 2013). Cravings for the stimulant's effects tend to linger, even after abstinence has been achieved, and the potential for recurrent use is high.

EXHIBIT 2.3. Continuum of Psychostimulant Activation


Increasing cognitive activation as stimulant dose increases initially produces increased wakefulness and cognitive enhancement. These are the beneficial effects. As dose or potency increases, a sense of power and euphoria can ensue. These are the effects people with SUD seek. Such effects are accompanied by cognitive deficits. Higher doses can result in overdose, psychosis, coma, and eventual circulatory collapse.

Source: Wood et al. (2014). Adapted with permission.

Effects of Combining Psychostimulants With Opioids

Psychostimulant-related overdose deaths involving opioids have been increasing over the past 20 years, with heroin and synthetic opioids (like fentanyl) largely accounting for psychostimulant-associated fatalities since 2010 (McCall Jones et al., 2017). Polysubstance use, specifically the co-consumption of synthetic opioids and psychostimulants, like cocaine and MA, was largely responsible for the increases in cocaine- and MA-related overdose deaths observed from 2012 to 2017 (Kariisa et al., 2019).

Opioids can lead to potentially lethal respiratory depression. This is especially true of fentanyl and fentanyl analogs, which are rapid acting and are increasingly being taken in combination with cocaine or MA, by accident or on purpose (LaRue et al., 2019). Fentanyl can induce fatal respiratory depression in as little as 2 minutes (Kuczyńska et al., 2018). Even if nonfatal, respiratory depression is dangerous and can lead to hypoxic brain injury (Kiyatkin, 2019). Because people naïve to opioids lack opioid tolerance, they may be at an increased risk of unintentional overdose when combining stimulants, like cocaine, with fentanyl or other synthetic and nonsynthetic opioids (LaRue et al., 2019).



Effects of Route of Administration

The five most common routes of administering psychoactive (mood-changing) substances are:

- Oral consumption (i.e., swallowing, gumming [rubbing the substance on the gums]).
- Intranasal consumption (i.e., insufflation).
- Inhalation into the lungs (i.e., smoking).
- Intravenously (i.e., injection).
- Vaginal or anal insertion.

Cocaine and MA can be smoked, snorted, injected, ingested orally, or absorbed intrarectally or intravaginally. Prescription stimulants can be taken orally or crushed and snorted. The route of administration affects the amount (i.e., the dosage) of stimulant delivered to the brain, the speed at which it is delivered, and the resulting intensity of the stimulant's effects—which in turn may affect the course of an SUD. Because a person's preferred route of administration affects the extent and depth of chronic effects, it has implications for treatment decisions (see Chapter 5). (For specific information on drug use and peak effects, see Chapter 3, Exhibit 3.2.)

The long plateau effect and the much longer half-life of MA versus cocaine suggest considerable dangers in repeated use of MA (Cruickshank & Dyer, 2009). Because stimulants exert their effects in a dose-dependent manner, the route of administration has serious neurologic, physical, psychiatric, and neurocognitive implications for the person using the stimulant. Prolonged high doses of stimulants (e.g., during binges or chronic use) may cause greater and longer lasting neurologic damage, which in turn may lead to greater and longer lasting cognitive deficits.

The onset of stimulants' chronic effects varies across individuals, and although there are few data to predict how long it will take for any person to begin experiencing the chronic effects of stimulant use, onset is probably related to:

- The amount of stimulant used.
- The frequency of use.
- The route of administration.
- Significant medical comorbidities.
- Co-occurring mental disorders.
- Co-administration of other substances.

- The environment in which the substance is taken.
- Genetics and metabolic factors.

However, in general, higher, more frequent doses of stimulants used in combination with other substances result in more rapid transition to the effects of chronic stimulant exposure. (For a discussion of route-of-administration effects on toxicity and adverse reactions, see Chapter 3.)

Psychological and Neurocognitive Effects

The immediate psychological effects of stimulant administration include a heightened sense of well-being, euphoria, excitement, and alertness, and increases in motor activity, similar to what would be seen in a manic state. Stimulants also reduce appetite and may result in insomnia. Stimulants may also enhance focus and libido (Volkow et al., 2007).

High doses, particularly in the setting of sleep deprivation, may result in restlessness, agitation, and more profound psychiatric presentation, including altered perceptions of reality and hallucinations. Chronic psychological effects of stimulant use and withdrawal may include paranoia, psychosis, depression, and/or suicidal ideation.

Cocaine

Routes of Administration

Cocaine is most commonly taken by nasal insufflation (snorting), intravenous injection, or inhalation of smoke vapors (smoking/inhalation). Less often, it is taken orally, vaginally, rectally, or sublingually. The half-life of cocaine is about 60 minutes (Coe et al., 2018) but can range from 40 to 90 minutes (ARUP Laboratories, 2019).

Pharmacology

Cocaine has two main pharmacologic actions. It is both a local anesthetic and a central nervous system (CNS) stimulant (NIDA, 2016a). Cocaine exerts its local anesthetic actions by blocking the conduction of sensory impulses within nerve cells. This effect is most pronounced when cocaine is applied to the skin or to mucous membranes. Cocaine has approved medical use as a local anesthetic in some surgery of the eye, ear, and throat (NIDA, 2016a).

As a CNS stimulant, cocaine affects a number of neurotransmitter systems, but it is through its interaction with the dopamine and the limbic reward system that cocaine produces some of its most important effects, including positive reinforcing effects (NIDA, 2016a). The major influence of cocaine on the dopamine system is its ability to block the synaptic reuptake of dopamine.

Cocaine does not directly stimulate the dopamine system; rather, it causes the system to be stimulated by preventing dopamine from being removed from the synaptic gap. Cocaine's blockade of the dopamine reuptake transporter extends the availability of dopamine in the synaptic space, where it continues to occupy the dopamine receptors and causes the postsynaptic neurons to fire for a longer-than-normal period (NIDA, 2016a). (See Exhibit 2.4.)

Acute Physiologic Effects

Acute cocaine use can lead to narrowing of the blood vessels and an increase in body temperature, pulse, and blood pressure (NIDA, 2016a) as well as


fatigue (Ciccarone, 2011). In some cases, tremors, dizziness, and muscle twitching can occur (NIDA, 2016a).


Acute Psychological Effects

The extended firing of the postsynaptic neurons resulting from prolonged dopamine receptor activity is initially experienced subjectively by people using cocaine as a positive sensation involving increased energy, arousal, and stimulation (NIDA, 2016a). The effects experienced during the initial period of cocaine use are generally mood altering in a positive manner. For most individuals, the subjective experience of the acute effects includes a generalized state of euphoria in combination with feelings of increased energy, talkativeness, mental alertness, and hypersensitivity to sight, sound, and touch (NIDA, 2016a).

Many people feel more intensely involved in their interactions with others and more playful and spontaneous when using cocaine. As patients use more, they may experience unpleasant adverse

EXHIBIT 2.4. Acute Effects of Cocaine on Dopamine Transmission





effects including increased anxiety, irritability, paranoia, and restlessness (NIDA, 2016a). As cocaine use subsides, particularly among patients with a stimulant use disorder, withdrawal symptoms will be present, including depressive symptoms and mood lability (Ciccarone, 2011).

With continued escalating use of cocaine, the individual becomes progressively tolerant to the positive effects and sensitized to the negative effects, which can increase the risk of unintentional overdose (NIDA, 2016a). People report that the positive effects of cocaine use are not as profound and that the rebound negative and adverse effects may increase over time, leading to a dysphoric, depressed state. This constant cycle of seeking additional positive effects and eliminating negative effects may perpetuate the cocaine use disorder. (For details on the medical aspects of acute cocaine use, see Chapter 3.)

Chronic Physiologic Effects

Initial experimental cocaine use often progresses to more steady use, requiring larger and larger doses to achieve the desired effects (NIDA, 2016a). Someone with regular cocaine use may become obsessed with the rituals of cocaine use and find that many common items or situations trigger cravings for the drug. Cocaine use disorder can develop, with overwhelming urges and cravings for cocaine, and an inability to self-limit or abstain from use.

The person addicted to cocaine will continue use despite the negative consequences. At this stage, the adverse consequences of cocaine use disorder have probably affected all aspects of the person's life.

There are no data that indicate how long it will take for any individual to begin to experience the chronic effects of cocaine use. Some individuals report an ability to use for extended periods with few signs of negative consequences. Others report a very dramatic onset of severe detrimental effects as soon as a few weeks or months after initiation of cocaine use. In general, however, similar to the effects of MA, the higher the doses and the more frequently the doses are administered, the more quickly the chronic effects of cocaine use will appear. In addition, intranasal administration (snorting) is associated with slower onset of chronic effects than is smoking cocaine (freebasing or smoking crack) or injecting it intravenously (Ciccarone, 2011).

Physically, the person with cocaine use disorder may appear thin or even emaciated. Personal hygiene and self-care may be neglected, and medical and dental needs may go unmet. Because cocaine suppresses appetite, the person fails to eat properly and may suffer from weight loss and nutritional deficiencies (Ciccarone, 2011). People with severe cocaine use disorder may ignore food, clothing, shelter, and sexual needs. Continued cocaine use can lead to erectile dysfunction and menstrual irregularities (Ciccarone, 2011), as well as anorexia, chest pain, and extreme fatigue.

Chronic Psychological Effects

Psychologically, cocaine's chronic effects oppose the often-desired initial effects. Chronic cocaine use increases paranoia and confusion (Ciccarone, 2011). The same substance that produced a mild sensation of arousal and decreased fatigue now causes insomnia and episodic depression.

Chronic use of cocaine may cause neuropsychological impairments (Quednow & Vonmoos, 2017; Spronk et al., 2013). Cocaine-induced cognitive deficits may affect multiple domains, but they appear to be reversible in patients with a mild or moderate cocaine use disorder within 1 year of cessation of use (Vonmoos et al., 2014).

The physical, psychological, and cognitive effects of chronic cocaine use reflect the underlying neurobiologic changes from cocaine's impact on the neurotransmitter dopamine. Spronk and colleagues (2013) found a strong association between the long-term use of cocaine and deficiencies in the following cognitive domains: attention, response inhibition (i.e., the ability to inhibit one's impulse to respond to a stimulus), working memory, cognitive flexibility, and psychomotor performance.

Although clinicians may easily pick up on the extensive health-compromising effects of cocaine use when examining the behavioral and psychological profile of patients entering SUD treatment, patients may need additional education to understand the correlation between their substance use and its negative health effects.

Methamphetamine

Routes of Administration

MA is typically taken orally, nasally (snorting/insufflation), intravenously, or by inhaling smoke vapors (smoking/inhalation). Less often, MA is taken vaginally, rectally, or sublingually. The half-life of a single dose of MA is about 10 hours across routes of administration (Cruickshank & Dyer, 2009).


Pharmacology

The course of MA use disorder development is similar to that of cocaine use disorder. The underlying neurologic effects of MA are similar to the effects produced by cocaine: essentially, it increases levels of free dopamine in the brain's limbic reward system. (Exhibit 2.5 illustrates some of the acute effects of MA on dopamine transmission.)

Research has demonstrated that MA has neurotoxic effects, but the mechanism of action of neurotoxicity is still being studied, although it seems to be multifactorial. Oxidative stress, excitotoxicity, and neuroinflammation have all produced signals related to the neurotoxic effects of MA (Paulus & Stewart, 2020; Yang et al., 2018). Because MA crosses neuronal cell membranes and enters the microscopic sacs (called vesicles) where neurons store dopamine, it is believed that damage to the storage sacs and the neurons' axonal endings causes dopamine to leak uncontrollably into the synapse. MA can also cause neurotoxicity indirectly by moving dopamine out of the storage sacs and into the neuron's cytoplasm (i.e., the cell's internal material), where it is converted to toxic and reactive chemicals. (Exhibit 2.5 shows some of these processes.)

Exhibit 2.6 includes key terms discussed in this chapter.

EXHIBIT 2.5. Acute Effects of Methamphetamine on Dopamine Transmission






EXHIBIT 2.6. Key Terms

Excitotoxicity: A complex process in which excessive activation of excitatory amino acid receptors causes the death of nerve cells in the nervous system. Excitotoxicity can lead to the production of free radicals and oxidative stress.

Neuroinflammation: The inflammation of tissue in the nervous system resulting from a cascade of immune responses to injury or illness.

Oxidative stress: Injury to tissues in the body due to an imbalance between free radicals that cause damage and antioxidants that repair damage. Free radicals are molecules produced during metabolic reactions or after exposure to certain environmental agents.

Additionally, glutamate accumulation and microglial activity changes associated with MA use may be related to MA's neurotoxic effects. Medications that block the inflammatory effects of microglial activation may help prevent MA's neurotoxicity (Yang et al., 2018).

Numerous animal studies have demonstrated that MA can damage both dopamine and serotonin systems (Chiu & Schenk, 2012; Shin et al., 2017; Yang et al., 2018). MA toxicity occurs after repeated high-dose administration, and it is selective for certain neuronal systems, particularly those in the limbic reward system (e.g., striatum, substantia nigra, nucleus accumbens). Within these brain circuits, MA has been shown to reduce the number of nerve fibers, impair normal physiologic functioning, and destroy both axons and axon terminals (i.e., synaptic junctions). These studies have also shown that MA toxicity is highly dependent on dose, route of administration, and the frequency with which the drug is taken.

Long-term use of MA may deplete dopamine levels, decrease dopamine receptors, and lower dopamine transporter levels (Yang et al., 2018). Some postmortem studies have shown that even recreational doses of MA significantly expend dopamine levels (Boileau et al., 2016). A review on the neurotoxicity of MA (Yang et al., 2018) implicates dopamine in numerous harmful effects of MA exposure, including increased

oxidative stress (i.e., an imbalance of free radicals and antioxidants in the body), impairments in mitochondrial metabolism, and inflammatory processes within the brain.

Prolonged or heavy use of MA decreases the brain's ability to manufacture dopamine. This impairment may persist for months or even years after one stops taking MA (Yang et al., 2018). Researchers believe that those changes in dopamine levels and the damage done to dopamine and serotonin neurons are responsible for the chronic effects of MA use (Shin et al., 2017).


Compared with cocaine, which is rapidly metabolized by plasma and tissue enzymes, MA is metabolized at a much slower rate, which results in a longer duration of action (NIDA, 2019a). Although the half-life of cocaine is about 1 hour, a single dose of MA may produce an effect for about 10 hours (Coe et al., 2018; Cruickshank & Dyer, 2009). MA's slower rate of metabolism extends the duration of its neurotoxic effects.

Acute Physiologic Effects

The acute physiologic effects of MA are generally similar to those of cocaine: increased heart and respiratory rates, elevated blood pressure and body temperature, and pupillary dilation (Matsumoto et al., 2014). Other acute effects include increased vigor, irregular heart rate, and damage to small blood vessels in the brain (Ciccarone, 2011; Kevil et al., 2019). Dangerously elevated body temperature and severe damage to the liver occur with high-dose MA (Matsumoto et al., 2014). If not treated immediately, these effects can result in death (Matsumoto et al., 2014).

Acute Psychological Effects

MA's psychological effects, like those of cocaine, include a heightened sense of well-being or euphoria, and increased alertness (Ciccarone, 2011). High doses may produce repetitive and compulsive acts and may cause irritability; excitement; visual, auditory, or tactile hallucinations; and altered perceptions of reality, characterized by delusions and psychosis (Bramness et al., 2012; Glasner-Edwards & Mooney, 2014; Wearne & Cornish, 2018). People using MA



may engage in protective behaviors in response to irrational fears brought on by altered perceptions of reality. Mood lability secondary to elevated dopamine levels is common. With continued use, tolerance develops to the behavioral effects, and repeated exposure may produce sensitization.

MA withdrawal is like that of cocaine, but because of the longer effects of MA, withdrawal may be more intense and protracted (Courtney & Ray, 2014).

Over the course of 1 to 14 days after last use, the person using MA experiences a drastic drop in mood and energy levels. Sleep—which may be promoted by the use of secondary substances such as alcohol, barbiturates, and benzodiazepines—finally begins and may last more or less uninterrupted for several days. Upon awakening, the individual may experience mild to severe depression (Zorick et al., 2010), perhaps lasting for several weeks. While in this depressed state, the person has an increased risk of suicide (Lerner & Klein, 2019).

Chronic Physiologic Effects

Understanding the chronic physiologic effects of MA use is essential for treatment providers who serve this population. Chronic use of MA may result in multiple dysfunctions of the heart (e.g., hypertension, aortic dissection, acute coronary syndromes, pulmonary hypertension, cardiomyopathy [Kevil et al., 2019; Paratz et al., 2016; Paulus & Stewart, 2020; Petit et al., 2012]) and, among people who inject the drug, skin abscesses (Yasaei & Saadabadi, 2021) and damaged blood vessels at the injection site. Chronic use may also lead to episodes of protective behaviors, paranoia, anxiety, confusion, and insomnia (Glasner-Edwards & Mooney, 2014). Heavy use is linked to progressive social and occupational deterioration. Psychotic symptoms may sometimes persist for months or years after use has ceased (Wearne & Cornish, 2018).

Some of the most concerning research findings about MA suggest that its prolonged use not only modifies behaviors, but changes the brain in fundamental and long-lasting ways. MA impairs the functioning of both the dopamine system and the serotonin system (serotonin is another important CNS neurotransmitter; Thomas et al., 2010) and


possibly other neurotransmitter systems (Ferrucci et al., 2019). MA-induced neuronal toxicity is specific to certain brain regions (primarily the limbic reward system), and this toxicity is reflected both biochemically and anatomically. Finally, these impairments in brain functioning may underlie the cognitive and emotional deficits seen in many people who use MA.

Chronic Psychological Effects

One of the potential negative effects of chronic MA use is psychosis. Patients with persistent psychosis are often treated with medications to return their brain functions to normal, and many antipsychotic medications work by affecting the activity of the dopamine and serotonin neurons. Current protocol in treating persistent MA psychosis is to manage the patient's symptoms—potentially through second-generation antipsychotics like olanzapine and risperidone—to try and improve overall quality of life and reduce the risk for recurrent use (Wearne & Cornish, 2018).

Characteristics of neurocognitive decline in people with MA use disorder are similar to those seen in patients with a cocaine use disorder. The changes to cognition are usually across multiple domains, including attention, psychomotor activity, memory, and decision making (Hart et al., 2012). Unlike with cocaine, the duration of the neurocognitive deficiencies has not been well described, but neuroimaging would suggest more long-lasting neurocognitive deficiencies likely related to the longer duration of action of MA itself and its more profound effect on the neuroplasticity of the brain.

Depletion of dopamine in the brains of people who use MA is similar to the loss of dopamine seen in patients with Parkinson's disease. Research has yet to define a clear correlation between MA use disorder and the Parkinson-like symptoms described by clinicians and patients (Christine et al., 2010; Granado et al., 2013; Kish et al., 2017). Determining the lasting effects of prolonged exposure to MA on the dopamine reward system may help clinicians better support patients entering recovery from MA use. Additionally, understanding how these Parkinsonian symptoms develop may reveal additional pathways for treatment of the condition and MA use disorder.



Prescription Stimulant Medications

Routes of Administration

Prescription stimulants are typically taken orally but, when misused, can also be taken intranasally (snorted; Yanofski, 2011). Half-lives vary by drug and by formulation (e.g., short acting versus long acting). For example, short-acting amphetamine has a half-life of approximately 9 hours, whereas the long-acting formulation has a half-life in the range of 10 to 13 hours (Pradeep & Standeven, 2019).

Pharmacology

Stimulant medications (e.g., *d*-amphetamine, mixed enantiomers/mixed salts amphetamine, lisdexamfetamine) exert their effect in much the same way that cocaine and MA do—by increasing levels of dopamine in the brain (NIDA, 2014). The prescription stimulants methylphenidate and *d*-amphetamine increase dopamine signaling—methylphenidate by blocking dopamine transporters and *d*-amphetamine by enhancing dopamine release from nerve terminals (Lakhan & Kirchgessner, 2012). Prescription stimulants are prescribed in such a way that, when taken appropriately, they produce slow and steady increases in dopamine (NIDA, 2014).

Acute Physiologic Effects

Acute adverse physiologic effects of stimulant medications include loss of appetite, insomnia, weight loss, headache, nausea, vomiting, abdominal cramps, increased blood pressure and heart rate, and, potentially, worsening of motor tics (Craig et al., 2015; Heal et al., 2013).

Chronic Physiologic Effects

Ongoing exposure to stimulants—such as repeatedly taking even the same doses of stimulant medication—can lead to tolerance to the stimulant, as well as tolerance to the brain's endogenous dopamine (Yanofski, 2011). This tolerance to dopamine means the brain becomes less sensitive to it; thus, it could become less sensitive to the medication's effects over time (Yanofski, 2011).

Other long-term effects of stimulant medication in children and adults are unclear, in part because of the lack of longitudinal treatment studies and poor long-term adherence to treatment (Molina & Swanson, 2020). For instance, it is unknown whether brain changes that occur with acute stimulant medication exposure (e.g., increased activation of areas of the prefrontal cortex that are normally underactive in ADHD) persist with chronic exposure (Molina & Swanson, 2020; Weyandt et al., 2013). There seems to be no link between prescription stimulants taken in adolescence and later development of SUDs (Quinn et al., 2017; Wilens et al., 2011). Appetite loss, headache, and digestive distress appear to continue with chronic use, but, again, few studies of long-term effects exist (Craig et al., 2015).

Acute Psychological Effects


Prescription stimulants are known to improve alertness, attention, and energy (NIDA, 2018b). Thus, much of the research on the short-term effects of these medications concerns cognitive functioning, including enhancement of several cognitive processes, such as attention, vigilance, response inhibition, memory, and working memory (D. M. Dougherty et al., 2016; Molina & Swanson, 2020; Swanson et al., 2011). People misusing prescription stimulants often do so because of the perceived neurocognitive benefit—largely that of improved concentration and alertness, such as for studying and academic performance (Clemow & Walker, 2014; Marraccini et al., 2016; Weyandt et al., 2013)—and not necessarily solely as a result of craving.

Chronic Psychological Effects

Research suggests that long-term use results in continued alleviation of ADHD symptoms, including inattention, hyperactivity, and impulsivity, but only while the medication is being taken (Craig et al., 2015).

Assessment and Diagnosis

Diagnosis can be based on criteria established in the fifth edition of the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-5; American Psychiatric Association [APA], 2013) for a stimulant use disorder




involving amphetamine or cocaine. For treatment reimbursement, the diagnosis may also need to reflect criteria according to the most recent version of the *International Classification of Diseases, Clinical Modification* (ICD–CM) found under “Coding” at <https://www.cms.gov/Medicare/Medicare> (the current version at the time of this Treatment Improvement

Protocol [TIP] update’s publication was ICD-10-CM). Arriving at a diagnosis is simplified by having information available from a relevant and accurate patient history, a urine toxicology screen or similar laboratory tests, and clinical observations of physical signs and mental status.

WHAT TO DO IF A PATIENT SCREENS POSITIVE FOR STIMULANT USE

- Primary care providers are on the front lines of identifying and helping manage SUDs in patients. Regular screening can help hasten diagnosis and referral for treatment. But once a patient screens positive for stimulant use, what should primary care physicians do? Best practices include the following (Substance Abuse and Mental Health Services Administration [SAMHSA], 2011):
- Leverage screening, brief intervention, and referral to treatment (SBIRT) techniques to get a better sense of the patient’s symptoms and severity, substance-related problems (e.g., with work, with relationships, legal problems), and treatment needs. (For more information about SBIRT, see the text box “Screening, Brief Intervention, and Referral to Treatment for SUDs: What Primary Care Providers Need to Know” in Chapter 3.)
- For mild or moderate stimulant use, a brief SBIRT intervention centered on education and motivational interviewing may be helpful in guiding patients toward acknowledging their problem behaviors and committing to behavior change. Using trained peer recovery support specialists can offer patients additional support and resources from people with lived experience with SUDs.
- For severe stimulant use, refer patients to qualified licensed mental health service providers and SUD treatment providers in the co-occurring disorders field for treatment and supportive services (e.g., for outpatient services, intensive outpatient programs, partial hospitalization services, residential programs, 12-Step programs such as Crystal Meth Anonymous).
- Use warm handoffs and other active referral linkages, rather than simply disseminating contact information, to increase the likelihood that patients will enter treatment. Providers should also have follow-up discussions with patients to ensure the referral was used. If the patient did not follow through, providers should talk with the patient to determine the reason and discuss how barriers to access can be overcome.
- Offer education about the dangers of taking stimulants laced with synthetic or nonsynthetic opioids—particularly cocaine with fentanyl, which is an increasingly popular and highly lethal combination. Educate patients and family members about the purpose of naloxone (to reverse opioid overdose) and how and when to administer it, and ensure that interested patients have a prescription for naloxone.
- For patients who inject drugs, also offer education about the importance of safer injection practices, how to obtain new needles and syringes, simple wound care techniques, and signs and symptoms of infection that warrant further medical intervention.
- For patients ambivalent about treatment, provide harm-reduction strategies and education. Providers should prescribe prevention medications like postexposure prophylaxis (nPEP) or pre-exposure prophylaxis (PrEP), screen for asymptomatic infections, provide overdose and overamping education, and create a plan for how to access treatment when the patient is ready.
- Where appropriate (e.g., when patients have a supportive family network), consider including family in the recovery process to give patients additional emotional support and resources to help with stopping stimulant use. (See SAMHSA’s TIP 39, *Substance Use Disorder Treatment and Family Therapy* [<https://store.samhsa.gov/product/treatment-improvement-protocol-tip-39-substance-use-disorder-treatment-and-family-therapy/PEP20-02-02-012>], for more guidance about the role of families in SUD treatment.)



History

An appropriate substance use history should include the substance(s) and medications used during the past 30 days; the specific substance(s) or combinations typically used with the usual dose, frequency, and route of administration; the duration of use; and the time and amount of last use (Substance Abuse and Mental Health Services Administration [SAMHSA], 2020I). If the patient has been bingeing, a brief description of this and previous episodes is helpful. In addition, the history should include information about any previous seizures, delirium tremens, heart and pulmonary problems, paranoid reactions (with or without altered perceptions of reality and hallucinations), and other serious medical and psychological conditions and psychiatric diagnoses and if they occurred pre- or post-stimulant use, as well as all medications the patient is taking. Additionally, check to see if there are substance use or psychiatric problems within the person's family (SAMHSA, 2020I).

For most patients presenting in an emergency department, the substance use and medical history will, of necessity, be brief and focus on the potential causes for the observed symptoms and complaints and any potential medical or psychological problems that are likely to complicate treatment and the patient's response. Emergency department personnel should stabilize the patient medically and assess potential danger to self and others before trying to take a history. Patients in a heightened state of arousal and experiencing persecutory perceptions may not give an accurate accounting of their current and past substance use. Information from significant others or from a reliable source can help clarify the patient's history. In situations where the patient is delirious, psychotic, or unable to respond, information from accompanying friends or significant others about the antecedents of the problem is particularly important. Sometimes, the substance use history must await symptomatic management.

The history may be supplemented by a variety of SUD screening instruments, although these are not notably reliable if used with individuals who are intoxicated or acutely psychotic.

A number of these screening instruments are described in detail in Appendix B of SAMHSA's TIP 42, *Substance Use Disorder Treatment for People With Co-Occurring Disorders* (<https://store.samhsa.gov/product/tip-42-substance-use-treatment-persons-co-occurring-disorders/PEP20-02-01-004>).

Urine Toxicology

A urine screen or toxicology test can be used to identify which substances the patient has used recently (Jaffe et al., 2016). This testing is vital to confirm clinicians' clinical assessments and observations. Some emergency departments have bedside or patient-side urine immunoassay testing kits (dipstick tests) that can be used for a quick turnaround without waiting on more formal assays. The kit's results can be validated by additional laboratory studies.

The results of either dipstick or Enzyme Multiplied Immunoassay Technique (EMIT) tests are appropriate to use for medical purposes. Alternative techniques for determining substance use are analyses of hair, blood, sweat, or tissue samples (Jaffe et al., 2016). In general, however, urine has become the standard method of determining substance use in an individual, and tests are readily available in the medical setting, whereas other types of testing are not (Jaffe et al., 2016). Urine screens are relatively inexpensive, with five-panel tests (i.e., tests for five different drugs) costing on average \$4 and 14-panel tests costing about \$7 (Jaffe et al., 2016). Both qualitative and quantitative urine assays are usually needed to verify use and time/amount taken. Repeated assays can be used to track elimination of stimulants from the system if large amounts have been detected.

Because no standard set of substances is tested in a urine substance screen, medical personnel should make certain that assays for suspected substances are included. Also, no toxicology screen can determine with certainty whether someone used any particular substance—or any substances at all. The detection limitations may be too broad or the specific substance may have been completely metabolized before a urine specimen was collected. A positive report will not necessarily indicate when the substance was last used.

Metabolites for some substances are detectable for days or weeks after last use but take some time after substance administration to be detectable in urine (K. E. Moeller et al., 2017).

MA can be detected in urine for approximately 48 hours following use, and cocaine metabolites may be detected for as long as 2 to 4 days following use (K. E. Moeller et al., 2017). Many prescription and over-the-counter medications (e.g., diet aids, cold remedies) contain phenylpropanolamine or ephedrine that may yield positive EMIT or radioimmunoassay tests for amphetamines. Certain agents (e.g., phenylpropanolamine, ephedrine) can produce cross-reactivity in amphetamine tests, causing immunoassays for the analysis of amphetamine-type substances to potentially produce false positives (K. E. Moeller et al., 2017). Urine screening tests are not confirmation of patient substance use but rather are one piece of information to help guide clinical decision making. Many substances may interact with an amphetamine screening test. For this reason, the preferred method for determination of stimulant substance use is confirmatory urine testing in the form of gas chromatography/mass spectrometry.

Physical Signs and Mental Status

Signs and symptoms of cocaine use can include extreme happiness or being very energetic; hypersensitivity to sight, sound, and touch; irritability; paranoia; and, in large amounts, bizarre and violent behavior (NIDA, 2016a). Signs of MA use can include increased attention, decreased fatigue, increased activity and wakefulness, decreased appetite, euphoric mood, (NIDA, 2019a) and, in large amounts, fever, sweating, tremors, a rapid heart rate, stroke, aggression, and paranoia (Radfar & Rawson, 2014). Increased sensitivity to noise, nervous physical activity like scratching, irritability, dizziness, confusion, extreme anorexia, convulsions, and blood pressure are also potential harmful effects of MA use (SAMHSA, 2018c). Prescription stimulant misuse can manifest as feelings of euphoria, but in large amounts can result in restlessness, tremors, overactive reflexes, rapid breathing, confusion, aggression, hallucinations, panic, high fever, muscle pains, and weakness (NIDA, 2018b).

Data acquired from monitoring vital signs (temperature, blood pressure, pulse rate, respiration rate) can be used to document physical indicators of stimulant use. In addition, observations of physical manifestations related to acute or chronic stimulant use and to withdrawal can be documented. Similarly, a variety of instruments exists to determine mental status, although observational data regarding psychological and mental status may be adequate (see Appendix B of TIP 42, *Substance Use Disorder Treatment for People With Co-Occurring Disorders* at <https://store.samhsa.gov/product/tip-42-substance-use-treatment-persons-co-occurring-disorders/PEP20-02-01-004>. [SAMHSA, 2020I]).


ASSESSING FOR COGNITIVE DEFICITS

Profound cerebrovascular dysfunctions can occur among people who use stimulants. Clinicians must remain vigilant for neurocognitive disorders, like delirium, as well as signs and symptoms of those disorders, like changes in memory or orientation, in patients with stimulant use because such disorders can hinder recovery. They do so by negatively affecting outcomes like abstinence and treatment retention and certain cognitive domains, like motivation and decision making (Copersino et al., 2012; Perry & Lawrence, 2017).

For indepth cognitive assessment, referral to a neuropsychologist or neuropsychiatrist may be warranted. For older adults with past or current stimulant use who are experiencing cognitive difficulties, also consider referring to a geriatrician.

Differential Diagnosis

In the diagnostic process, other disorders and conditions with similar or identical presentations must be considered. Many people with stimulant use disorder have coexisting mental illnesses such as bipolar disorder and borderline personality disorder, which share some symptoms with stimulant use disorders (SAMHSA, 2020I). A heart attack, seizure, or other type of adverse medical event that can be brought on by stimulant



toxicity may instead have a different cause. The cause of the symptoms or adverse events must be determined for optimal continuing care and medical management.

Before a differential diagnosis of a coexisting mental disorder can be made, the patient must be abstinent for at least 4 weeks following cessation of withdrawal or severe intoxication (APA, 2013). The presenting psychiatric syndrome and symptoms can be treated meanwhile, and a diagnosis of unspecified schizophrenia spectrum and other psychotic disorders can be given. More information regarding the diagnostic process for patients with symptoms that indicate coexisting substance use and mental disorders can be found in TIP 42, *Substance Use Disorder Treatment for People With Co-Occurring Disorders* (<https://store.samhsa.gov/product/tip-42-substance-use-treatment-persons-co-occurring-disorders/PEP20-02-01-004>).

New forms of brain imaging techniques could offer a promising approach for making certain differential diagnoses—for example, if current research determines that these techniques are useful for distinguishing among drug-induced and other forms of psychosis.

Summary

Research has shown how stimulants such as cocaine, MA, and prescription stimulants exert their effects on the nervous system and affect feelings, emotional response, and behavior. There is now a greater understanding of neurologic systems related to reward and reinforcement, the development of stimulant use disorders, and the roles that craving and memory play in sustaining SUDs. Existing research can also help guide treatment approaches. Although more research is needed on the long-term neurologic, medical, psychiatric, and neurocognitive effects of stimulants in humans, animal studies have demonstrated cocaine's and MA's ability to disrupt normal brain function and cause long-lasting and perhaps permanent neurologic impairments. Continuing research and emerging imaging technologies will assist in the development of new and improved approaches for treating stimulant use disorders. Assessment of people with stimulant use should involve taking a thorough history, complemented by urine toxicology and data from physical observations. For less severe stimulant use, clinicians can use screening, brief intervention, and referral to treatment techniques to help guide patients toward behavior change. Patients with severe stimulant use disorder should be referred for specialized SUD treatment.

Appendix A: Treatment for Stimulant Use Disorders (TIP 33) Module 1

Directions: To receive credits for this course, you are required to take a post test and receive a passing score. We have set a minimum standard of 80% as the passing score to assure the highest standard of knowledge retention and understanding. The test is comprised of multiple choice and/or true/false questions that will investigate your knowledge and understanding of the materials found in this CEU Matrix – The Institute for Addiction and Criminal Justice distance learning course.

After you complete your reading and review of this material, you will need to answer each of the test questions.

Submit your test via the Internet. All of our tests are posted electronically, allowing immediate test results and quicker processing. First, you may want to answer your post test questions using the answer sheet found at the end of this appendix. Then, return to your browser and go to the Student Center located at:

<http://www.ceumatrix.com/studentcenter>

Once there, log in as a Returning Customer using your Email Address and Password. Then click on 'Take Exam' and you will be presented with the electronic exam.

To take the exam, simply select from the choices of "a" through "e" for each multiple choice question. For true/false questions, select either "a" for true, or "b" for false. Once you are done, simply click on the submit button at the bottom of the page. Your exam will be graded and you will receive your results immediately. If your score is 80% or greater you will have access to the Certificate of Completion. This is the final step in the process, and you may save and/or print your Certificate of Completion.

If, however, you do not achieve a passing score of at least 80%, you will need to review the course material and return to the Student Center to resubmit your answers.

If you have any difficulty with this process, or need assistance, please e-mail us at ceumatrix@ceumatrix.com and ask for help.

Answer the following questions by selecting the most appropriate response.

Quiz

1. What is the primary focus of the TIP regarding stimulants?
 - A. Cocaine and its derivatives
 - B. Caffeine and nicotine
 - C. Prescription stimulants
 - D. Alcohol and tobacco

2. What was the average price of methamphetamine in the United States from 2013 to 2017?
 - A. \$68
 - B. \$56
 - C. \$75
 - D. \$50

3. What percentage of adults with past-year methamphetamine use met the criteria for methamphetamine use disorder?
 - A. 40 percent
 - B. 70 percent
 - C. 60 percent
 - D. 53 percent

4. What is the definition of 'substance use disorder' according to DSM-5?
 - A. A social issue affecting communities
 - B. A psychological condition caused by stress
 - C. A medical illness caused by repeated misuse of a substance
 - D. A temporary condition that resolves on its own

5. Which demographic had the highest crude death rate from cocaine use according to the document?
 - A. Whites
 - B. Blacks/African Americans
 - C. American Indian/Alaska Natives
 - D. Hispanics

6. What major change in the brain is associated with stimulant use disorders according to the document?
 - A. Enhanced learning capabilities
 - B. Increased memory retention
 - C. Neurotoxic effects on cognitive functions
 - D. Improved decision-making

7. Which act allows healthcare professionals to offer FDA-approved narcotic medication treatment for opioid use disorder in various settings?

- A. Fair Sentencing Act of 2010
- B. Combat Methamphetamine Epidemic Act of 2005
- C. Drug Addiction Treatment Act of 2000
- D. 21st Century Cures Act of 2016

8. What percentage increase in ADHD prescription medication claims was reported among privately insured women ages 15 to 44 between 2013 and 2015?

- A. 344 percent
- B. 28 percent
- C. 4.8 percent
- D. 6.1 percent

9. Which brain structures are mentioned as important in the perpetuation of stimulant use disorders?

- A. Limbic system, occipital lobe, temporal lobe
- B. Hippocampus, thalamus, cerebellum
- C. Cerebral cortex, medulla, pons
- D. Basal ganglia, amygdala, prefrontal cortex

10. What is one strategy suggested for prescribers to prevent stimulant medication misuse?

- A. Educating patients about sharing medications
- B. Increasing the number of pills prescribed
- C. Prescribing immediate-release formulations
- D. Avoiding medication contracts

11. What role does dopamine play in the brain's reward system according to the document?

- A. It inhibits neurotransmitter release
- B. It regulates feelings of pleasure
- C. It causes withdrawal symptoms
- D. It enhances memory retention

12. Which model emphasizes the influence of social interactions and behaviors on substance use disorders (SUDs)?

- A. Biopsychosocial model
- B. Moral model
- C. Social learning model
- D. Sociocultural model

13. What is a significant factor that contributes to the neuroplasticity of the brain throughout a person's lifespan?

- A. Genetic predisposition
- B. Environmental influences
- C. Social interactions
- D. Chronic substance use

14. What physiological component is highlighted as important in understanding substance use disorders (SUDs)?
- A. Cognitive behavior
 - B. Cultural beliefs
 - C. Social stigma
 - D. Genetics
15. What is the effect of cue-induced drug craving on the brain according to the document?
- A. It decreases motivation
 - B. It triggers emotional responses
 - C. It activates memory-related brain systems
 - D. It leads to immediate withdrawal symptoms
16. How does the mechanism of action of prescription stimulants differ from that of cocaine and MA?
- A. It is drastically different
 - B. It is similar but varies by individual
 - C. It has no effect on dopamine
 - D. It only affects serotonin levels
17. What are the potential consequences of high doses of stimulants over time?
- A. Increased energy and focus
 - B. Enhanced memory retention
 - C. Cognitive impairments and medical complications
 - D. Improved emotional stability
18. What structural brain changes are associated with cocaine and amphetamine use?
- A. Increased gray matter in the prefrontal cortex
 - B. Increased white matter in the corpus callosum
 - C. No changes in brain structure
 - D. Reduced gray matter in specific brain regions
19. What is a significant risk associated with the combination of synthetic opioids and psychostimulants?
- A. Increased tolerance to stimulants
 - B. Fatal respiratory depression
 - C. Improved cognitive function
 - D. Reduced cravings for stimulants
20. What is the effect of the route of administration on stimulant use?
- A. It has no effect on the user
 - B. It only affects the taste of the substance
 - C. It influences the neurological and physical implications
 - D. It determines the legal status of the substance

21. What are some of the acute psychological effects of methamphetamine (MA) use as mentioned in the document?

- A. Increased energy and euphoria
- B. Decreased alertness and fatigue
- C. Heightened sense of reality and calmness
- D. Increased appetite and sleepiness

22. According to the document, what is a significant long-term effect of methamphetamine on the brain?

- A. Increased serotonin levels
- B. Neuronal toxicity specific to certain brain regions
- C. Enhanced cognitive flexibility
- D. Improved psychomotor performance

23. What physiological changes occur with acute cocaine use as described in the document?

- A. Decreased heart rate and blood pressure
- B. Increased body temperature and pulse
- C. Increased appetite and energy
- D. Decreased respiratory rate

24. What is the relationship between cocaine use and dopamine according to the document?

- A. Cocaine stimulates dopamine production directly
- B. Cocaine decreases dopamine receptor sensitivity
- C. Cocaine has no effect on dopamine levels
- D. Cocaine blocks the reuptake of dopamine

25. What chronic psychological effect is associated with cocaine use as per the document?

- A. Increased sociability
- B. Enhanced cognitive flexibility
- C. Paranoia and confusion
- D. Improved mood stability

26. What is a recommended strategy for patients who are ambivalent about treatment for stimulant use disorders?

- A. Provide harm-reduction strategies and education
- B. Encourage immediate hospitalization
- C. Suggest complete abstinence from all substances
- D. Ignore their concerns

27. Which of the following is a potential harmful effect of methamphetamine (MA) use?

- A. Increased appetite

- B. Euphoria
- C. Rapid heart rate
- D. Improved cognitive function

28. What should clinicians monitor to document physical indicators of stimulant use?

- A. Patient's mood
- B. Vital signs such as temperature and blood pressure
- C. Family history of substance use
- D. Patient's dietary habits

29. What is the significance of using warm handoffs in the referral process for patients with stimulant use disorders?

- A. To ensure patients enter treatment more effectively
- B. To reduce paperwork
- C. To increase the number of referrals
- D. To provide patients with more options

30. What is the role of new brain imaging techniques in the context of stimulant use disorders?

- A. To enhance the effectiveness of treatment
- B. To provide a cure for stimulant use disorders
- C. To replace traditional diagnostic methods
- D. To distinguish between drug-induced and other forms of psychosis

Name: _____

- | | |
|-------------------------|-------------------------|
| 1. [A] [B] [C] [D] [E] | 16. [A] [B] [C] [D] [E] |
| 2. [A] [B] [C] [D] [E] | 17. [A] [B] [C] [D] [E] |
| 3. [A] [B] [C] [D] [E] | 18. [A] [B] [C] [D] [E] |
| 4. [A] [B] [C] [D] [E] | 19. [A] [B] [C] [D] [E] |
| 5. [A] [B] [C] [D] [E] | 20. [A] [B] [C] [D] [E] |
| 6. [A] [B] [C] [D] [E] | 21. [A] [B] [C] [D] [E] |
| 7. [A] [B] [C] [D] [E] | 22. [A] [B] [C] [D] [E] |
| 8. [A] [B] [C] [D] [E] | 23. [A] [B] [C] [D] [E] |
| 9. [A] [B] [C] [D] [E] | 24. [A] [B] [C] [D] [E] |
| 10. [A] [B] [C] [D] [E] | 25. [A] [B] [C] [D] [E] |
| 11. [A] [B] [C] [D] [E] | 26. [A] [B] [C] [D] [E] |
| 12. [A] [B] [C] [D] [E] | 27. [A] [B] [C] [D] [E] |
| 13. [A] [B] [C] [D] [E] | 28. [A] [B] [C] [D] [E] |
| 14. [A] [B] [C] [D] [E] | 29. [A] [B] [C] [D] [E] |
| 15. [A] [B] [C] [D] [E] | 30. [A] [B] [C] [D] [E] |